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1
GENERAL INTRODUCTION 
 
There are approximately 150 species of Candida out of which only small 
numbers are able to establish pathogenesis in humans [1].  Out of the list of all 
these species, Candida albicans is the most commonly isolated species 
associated with infection. Diseases range from superficial mucosal infections to 
systemic mycoses.  Under normal conditions, C. albicans exists as a common 
member of the oral, gastro-intestinal, and uro-genital microbiota, with carriage 
rates ranging from 30-70% among healthy individuals [2, 3].  However, exposure 
rates are likely much higher as the majority of individuals have circulating anti-
Candida antibodies [4].  Under conditions that permit outgrowth or invasion, C. 
albicans has the potential to cause infection and disease.  Therefore, a balanced 
immune response is required to defend against damaging infections, while 
tolerating mucosal colonization.  However, the mechanism controlling the host-
pathogen relationship is relatively unknown.   
Previous studies by Noverr et al. demonstrated the ability of C. albicans to 
produce immunomodulatory molecules called oxylipins, which are similar in 
structure and function to host eicosanoids.  Eicosanoids are a family of lipid 
immune signaling compounds that include the prostaglandins and leukotrienes.  
Specifically, C. albicans produces a compound that cross reacts with mammalian 
prostaglandin E2 (PGE2), called PGEx [2].  Very little is known about the 
immunomodulatory roles that PGE2 or PGEx plays during candidiasis.   Our 
hypothesis is that production of oxylipins by both fungi and host are crucial in 
 2
modulating the microbiology of the fungus and the host-pathogen interaction in 
favor of chronic infection or pathogenesis. The goal of this thesis project was to 
investigate the roles of both host and Candida produced eicosanoids during host-
pathogen interactions both in vitro and in vivo.  This involved investigating 
interactions with phagocytic and antigen presenting cells and how these cells 
influence downstream adaptive immune responses during systemic infection.  In 
addition, we investigated effects of host eicosanoids and eicosanoid inhibitors 
during pathogenesis of mucosal and systemic infections. The results of these 
studies are clinically significant and may help direct novel pharmacotherapeutic 
strategies to treat fungal infections.  
 
Virulence Attributes of Candida albicans.  C. albicans is an opportunistic 
pathogen that normally resides at mucosal surfaces asymptomatically.  
Therefore, it is not under selective pressure to develop traditional virulence 
factors found in professional pathogenic microbes.  Virulence factors in C. 
albicans are often the factors that allow the organism to persist within the host at 
mucosal surfaces and systemically.  In fact genetic deletion of many Candida 
“virulence factors” results in avirulence during both mucosal and systemic 
infection models.  It may therefore be more appropriate to define virulence in 
terms of traits required for survival within the host and evasion from host 
defenses.  Virulence traits in Candida includes adhesion to host surfaces, 
morphogenesis, biofilm formation, antigenic or phenotypic switching, tissue and 
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non-phagocytic invasion (via proteases and phospholipases), and intracellular 
survival strategies [5-7].   
 
Morphogenesis  
C. albicans is polymorphic and has the ability to grow both as yeast 
(blastospores), and as hyphae and pseudohyphae (filamentous form). The 
conversion from yeast to hyphae is induced by environmental conditions such as 
growth at 37°C, serum, pH > 6.5, D-glucose, CO2, and nitrogen and carbon 
starvation (reviewed in [8]).  In addition, C. albicans produces quorum-sensing 
compounds that control morphogenesis. At high population densities, farnesol 
accumulates and represses hyphal formation, whereas tyrosol promotes 
germination at low population densities when farnesol concentrations are low  [9]. 
In addition, it was discovered that bacterial products influence morphogenesis.  
Pseudomonas aeruginosa produces a 12 carbon compound called dodecanol, 
which inhibits morphogenesis, indicating an antagonistic relationship.  Another 
study demonstrated that active serum fractions that promote hyphal formation 
contain bacterial peptidoglycan (PGN)-like molecules [25]. Analysis of purified 
bacterial products showed that synthetic muramyl dipeptides (MDPs), subunits of 
PGN, can strongly promote C. albicans hyphal growth. Multiple signal 
transduction pathways regulate hyphal development, including mitogen activated 
protein kinase (MAPK) cascades, pH-dependent signaling cascades, and cAMP-
dependent protein kinase A (PKA) pathways [10]. These pathways sense and 
respond to divergent and overlapping environmental signals. Therefore, C. 
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albicans control of morphogenesis can be fine tuned within the various host 
niches.   
The yeast forms are more often associated with asymptomatic 
colonization whereas the hyphal form is associated with infection and disease. 
Genes that control hyphal morphogenesis are co-regulated with genes encoding 
virulence factors such as proteases and adhesions [11]. The ability to switch 
between yeast and filamentous forms is also required for virulence as mutants 
that are “locked” in either the yeast form or the hyphal form are avirulent [11, 12].  
One study demonstrated that there are distinct roles for both yeast and hyphae in 
pathogenesis [13].  They engineered a strain that carries one copy of NRG1, a 
key negative regulator of hyphal development, under the control of a tetracycline-
regulatable promoter so the growth forms of the strain can be controlled in vivo. 
Mice injected with this strain under conditions permitting hyphal formation 
succumbed to the infection, whereas all of the animals injected under conditions 
that inhibited this transition survived. Importantly, fungal burdens were almost 
identical in both sets of animals, indicating that, whereas filament formation 
appears to be required for the mortality resulting from a deep-seated infection, 
yeast cells play an important role early in the infectious process by extravasating 
and disseminating to the target organs. This indicates that hyphal formation is 
required for mortality via an unknown mechanism.  Therefore, this suggests that 
there are morphotype specific factors and/or immune responses that influence 
survival. 
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Biofilm Formation   
Another role that morphogenesis plays in the lifestyle of C. albicans is in 
the ability to form biofilms, which are complex aggregations of microbial cells 
attached to a solid surface, marked by the excretion of a extracellular 
polysaccharide matrix (ECM) [reviewed in [14-16]. Biofilm formation requires the 
ability to undergo morphogenesis with germination being induced upon contact 
with an appropriate surface [17, 18].  Mutants of C. albicans that are unable to 
form hyphae also are unable to form vigorous biofilms.  In addition, 
environmental conditions that induce hyphal formation also facilitate biofilm 
formation. C. albicans readily forms biofilms on abiotic surfaces such as synthetic 
polymers used in medical devices.  In addition, recent studies using experimental 
models of infection have shown that C. albicans forms biofilms on biotic surfaces 
such as oral and vaginal mucosal tissues in vivo [19, 20]. 
Biofilm formation occurs in distinct developmental stages:  attachment, 
proliferation, hyphal transformation, maturation, and dispersal [9, 21]. The 
maturation stage involves a repression of yeast growth, and a proliferation of 
hyphal growth elevated combined with secretion of ECM.  The matrix is 
composed of carbohydrates, protein, phosphorus, hexosamines, and glucose; 
however, a large amount of material remains uncharacterized [22].  Further 
studies by Mukherjee et al. have indicated that the composition of ECM (the 
protein and the carbohydrate component) varies depending on the biofilm 
developmental stage [15].  Macromolecular studies have been difficult but one 
study demonstrated the cell wall component -glucan could be detected in biofilm 
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ECM [23].  This is of significance because -glucan is recognized by dectin-1, a 
pathogen recognition receptor (PRR), and could influence interactions with the 
host [24-26].  
Studies have shown that C. albicans biofilms are highly heterogeneous in 
terms of structural architecture, which varies greatly by the nature of the 
substrate surface.  For instance biofilms formed on polyvinyl chloride disc have 
distinct composition compared to that formed on silicone elastomer or 
polymethylmethacrylate denture strips [15, 27] .  Unlike the nature of the 
substrate resulting in different composition of biofilms, different environmental 
factors (pH, oxygen availability, fluid shear and redox-gradients) does not seem 
to be playing role in designing the architecture of the C. albicans biofilms.   
Similar levels of transcript profiles were detected from the biofilms growing under 
different environmental conditions.   
In terms of infection, Candida biofilms readily form on indwelling medical 
devices and represent one of the main portals of entry for systemic and tissue 
candidiasis [28].  It is estimated that the majority of microbial infections originate 
from biofilms, with biofilm infection of indwelling medical devices being the single 
most important cause of nosocomial bloodstream infections (BSI).  To 
underscore this point, it is estimated that 250,000 - 500,000 device-related BSIs 
occur annually in the US.  Among those infections, 10% are caused by C. 
albicans, which has the highest mortality rate (40%) of all BSI causing organisms 
[29, 30].   Another feature of C. albicans biofilms is that they are highly resistant 
to antifungal agents [31].  The mechanism underlying this increased resistance is 
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not well understood; however, poor antifungal penetration has been ruled out 
[32].  Genomic studies have shown that biofilms exhibit unique gene expression 
patterns compared with planktonic cells, including upregulation of multi-drug 
resistance pumps [33-35].  The gene pathways that control biofilm formation are 
still being dissected.  There is some overlap with pathways that control 
morphogenesis; however, a specific biofilm regulator, Bcr1, is required for normal 
biofilm formation and can still form hyphae.  Therefore, biofilms represent a 
unique lifestyle for C. albicans, which requires significant investigation in terms of 
pathogenesis. 
 
Overview of the Immune Response to C. albicans Infections.  C. albicans 
causes both superficial mucosal infections and deadly systemic infections which 
involve the bloodstream and tissues.  The type of risk factors and appropriate 
immune response to infection varies depending on the type of infection. C. 
albicans resides at mucosal surfaces as a commensal organism, where immune 
responses must be tightly controlled to both prevent overgrowth and infection but 
also to prevent over-exuberant inflammatory responses.  Control of mucosal 
infections and clearance of systemic infections require both effective innate and 
adaptive immune responses.  The inflammatory response to fungal infections 
must be followed by resolution of inflammation, which is essential for limiting host 
damage.  Fungal infections tend to be chronic, which indicates that the immune 
system maintains a very precarious balance between tolerance and 
inflammation.   
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Mucosal Infections 
C. albicans is frequently isolated from the mucosal regions of vagina, oral 
cavity and gastrointestinal tract and can be carried asymptomatically in healthy 
individuals [36, 37].  Changes in the host environment can lead to fungal 
overgrowth and/or imbalances in host immune responses leading to symptomatic 
mucosal infection. Risk factors for mucosal infection are tissue specific and 
include host factors (immunosuppression) and environmental factors (antibiotics 
and hormones).   
 
Vaginal infection:  About 75% of women have at least one incidence of 
vulvovaginal candidiasis in their lifetime with about 5-10% recurrence rate [38, 
39].  Antibiotic treatment, oral contraceptives, hormone replacement therapy, 
pregnancy, immunosuppressive therapy are the several known predisposing 
factors leading to this disease [38-40].  In case of vaginitis the resistance and 
susceptibility is not dependent on adaptive immune responses.  This is supported 
by the fact that women with HIV infection, who are susceptible to oropharyngeal 
candidiasis (OPC), were no more susceptible to vulvovaginal candidiasis (VVC) 
than the healthy HIV- population [41].  In addition, experimental models show no 
role for cell mediated or humoral immunity. In understanding why adaptive 
immunity is not engaged in vaginal infections, studies have indicated that a 
strong regulatory immune response is present.  Regulatory T cells (Tregs), 
transforming growth factor  (TGF-) and plasmacytoid dendritic cells (DCs) were 
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present at the vaginal mucosa, which can inhibit inflammatory T cell responses 
[42-44].  Regulatory T cells (Treg) are responsible for dampening inflammation 
and promoting tolerance at mucosal surfaces via production of IL-10 and TGF-β 
[45].  In addition, homing receptors on T cells in the draining lymph nodes were 
down-regulated, indicating an inability to traffic to the vaginal mucosa.   
Instead, it is believed that susceptibility is controlled by innate immunity. 
The vast majority of symptomatic infections in women have increased neutrophil 
infiltrate that correlated with the observed symptoms of vaginitis. In fact, 
neutrophil infiltration showed a positive correlation to high vaginal fungal burden. 
Conversely, those women in these studies who presented as asymptomatic 
showed no evidence of neutrophil infiltration or inflammation. However, these 
neutrophil have defective antifungal activity and therefore may contribute to 
pathology rather than control infection.  It has been proposed that a threshold 
number of C. albicans cells is necessary to stimulate the neutrophil response and 
symptoms of disease, but that the threshold needed varies depending on the 
individual [46].  Vaginal epithelial cells also exert a fungistatic activity, which is 
reduced in women with recurrent vaginitis [47]. In addition, these epithelial cells 
can sense and respond to Candida cells and signal the chemotaxis of neutrophils 
[48]. Therefore, differences in the sensitivity of vaginal epithelial cells may be 
involved in determining susceptibility. 
 
Oral infection: There are several types of oral candidiasis including OPC, which 
is associated with T cell deficiency (HIV and neonates), and denture stomatitis, 
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which is associated with a contaminated indwelling device but occurs in 
otherwise healthy individuals.  There is a lack of studies investigating denture 
stomatitis.  One study demonstrated that both Th1 and Th2 cytokines are 
produced in patients [49].  Therefore, disease is not likely due to a Th1 
deficiency. Instead the Th1-type immune response is active but seemingly fails to 
resolve or protect against infection. This could be due to the serial feeding of the 
tissue with Candida as a biofilm on the denture material resulting in the chronic 
inflammation associated with infection. 
OPC involves infections of the palate, tongue and buccal mucosa and can 
either be pseudomembranous (thrush) or erythematous and is considered an 
AIDS defining illness [50].  Dissemination of infection generally does not progress 
from oral infections.  While it is clear that CD4+ T cells and adaptive immunity is 
required for defense against OPC, innate defenses also play a role in controlling 
fungal growth.  Epithelial cells can inhibit up to 80% of Candida growth by 
involving static mechanisms or production of cytokines [51-58].  In addition, 
saliva contains antimicrobial secretions consisting of calprotectin, β-defensins, 
and histatins [59, 60].  Along with epithelial cells, neutrophils are described to 
play role in innate immune responses though it is controversial [8, 61].  Studies 
have demonstrated reduced numbers of Langherhan cells in patients with 
frequent oral candidiasis incidences indicating that DCs might have some key 
role to play towards clearance of Candida. [62]. 
Adaptive immune responses largely involve cell-mediated immunity, while  
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humoral immunity does not appear to play a role in protection against or  
susceptibility to OPC [63].  Clinically, OPC is most common in HIV+ patients 
when CD4+ cell numbers drop below 200 cells/μl [64].  Overall, the prevalence of 
OPC depends on the status of the local immune mechanisms. Indeed some 
individuals with <200 CD4+ cells/μl never have OPC while others have recurrent 
episodes of OPC. Under conditions of CD4+ T cell deficiency it has been 
proposed that aside from innate defenses, CD8+ T cells help control C. albicans 
and that susceptibility is associated with defects in trafficking of cells to the site of 
infection [65].  In deciphering how CD4+ T cells control oral C. albicans levels, it 
was proposed that a Th1 response is required.  However, recent studies in 
experimental models have indicated the role of Th17 cells as well towards 
inducing protection against oral candidiasis [66]. Interestingly, knockout mice 
lacking IL-23 or IL-17R (Th17-deficient) were highly susceptible to OPC, whereas 
mice lacking IL-12 (Th1-deficient) were relatively resistant to infection.   
 
Gastro-intestinal infection:  Under normal conditions, humans are colonized with 
about 1014 microorganisms in the GI tract, most of them being bacteria.  Fungi 
are also important part of the microbiota and Candida is one of the most 
commonly isolated genus.  Under healthy host conditions, the Candida carriage 
rate inside the GI tract varies somewhere from 30-70% [2, 3]. Increases in GI 
colonization with Candida combined with immunosuppression can lead to spread 
into the bloodstream, an infection known as candidiasis of endogenous origin 
[67-70].  Risk factors include antibiotic treatment and parenteral nutrition, which 
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alter the bacterial microbiota leaving a niche for Candida overgrowth.  In addition, 
patients undergoing immunosuppressive treatment and cancer patients are 
particularly at risk of developing GI candidiasis.  One of the major problems 
associated with GI infection is that it is not clinically detected during the early 
stages of infection due to inconspicuous symptoms and the inability to 
differentiate commensal Candida from a pathogenic type. 
Both innate and adaptive immune responses are important for protecting 
against gastro-intestinal candidiasis.  The key immune cell players involved in 
initiating potent innate immune responses are NK cells, macrophages and 
neutrophils.  This was verified when gnotobiotic immunodeficient mice with 
defects in granulocytic cells showed susceptibility to candidiasis.  However, 
Candida-specific T cell and antibody responses were mounted, and eventually 
cleared the infection [71].  Treatment with the inhibitors of nitric oxide synthase 
(NOS) increased the magnitude of GI candidiasis severity. However, peroxynitrite 
was the responsible player, as nitric oxide is not candidacidal directly [71].  
These studies indicate that these reactive oxygen species released by the 
phagocytes are important in controlling Candida.   
Regarding adaptive immunity, studies using congenitally athymic T cell 
deficient (nu/nu), severe combined immunodeficient (SCID; no T or B cells) mice, 
or mice specifically lacking α/β or γ/δ T cells have shown that T cells are critical 
for effective protection against GI candidiasis (6, 9, 31, 104). Mice with T cell 
deficiencies were more susceptible to GI tract infection, but were not susceptible 
to sublethal intravenous challenge or dissemination from the GI tract. Various 
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studies have indicated that during GI candidiasis, Th1 responses are associated 
with protection whereas the Th2 responses induce non-protective phenotype [72-
76]. Antibody mediated protection against GI candidiasis have not been reported 
and mice lacking B cells are not susceptible to infection [77].  A study indicated 
that oral immunization had no role in decreasing the colonization of GI tract [78]. 
More recent studies have investigated the role of DCs in GI infections. 
Using an experimental murine model, it was demonstrated that Peyer’s patch 
DCs can discriminate between yeast and hyphal forms of C. albicans and 
promote differentiation of inflammatory (Th17/Th1) and tolerogenic DCs 
(Th2/Treg), respectively [79]. In addition, exacerbation of a Th17 response, 
characterized by uncontrolled inflammation and dampening of Th1 responses via 
IL-23 and IL-17, also leads to a worsening of fungal disease in the GI tract [79]. 
These observations contradict previous studies which demonstrated that yeast 
promote Th1 responses while hyphae promote Th2 responses from human 
dendritic cells [80].  It is possible that these differences are due to differences in 
dendritic cells or the experimental model used.  
In the context of C. albicans mucosal infections, Tregs are required for 
effective control of protective Th1 inflammation, which prevents eradication of 
infection.  This not only facilitates generation of memory immunity but also limits 
pathological inflammatory responses to persistent colonization [81, 82]. 
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Systemic Infections 
Systemic candidiasis is an infection associated with high morbidity and 
mortality.  Infections are often misdiagnosed, and delayed treatment combined 
with drug resistance has resulted in a 40% of crude mortality rate [30, 83, 84].  
The total number of Candida sp. cases in the U.S. ranges from approximately 
10,500 to 42,000 infections per year and is the fourth leading cause of 
bloodstream infections [85].   At present overall systemic candidiasis rates are on 
a rise and are associated with enormous amounts of health and economic losses 
[86].  Risk factors include immune deficiency associated with neutropenic, organ 
transplant, and cancer patients, use of immunosuppressive drugs, and indwelling 
medical devices. There are two major pathways by which C. albicans may enter 
the bloodstream: penetration from the GI tract into blood vessels and direct 
transmission via intravascular catheters [86-88]. 
Cells of the innate immune response represent the first line of defense 
against C. albicans infections and include effector cells with potent antifungal 
activity: neutrophils and macrophages [89-91].  While neutrophils generally kill 
via secreted enzymes and oxidative intermediates, macrophages can 
phagocytose C. albicans and kill via lysosomal and oxidative pathways.  In 
addition, innate immune cells serve in the initial recognition of C. albicans via 
pathogen recognition receptor (PRR) signaling.  PRRs, including toll-like 
receptors (TLRs) and lectins recognize cell wall components of C. albicans.  
Innate cells express PRRs and respond by secreting a variety of immune 
signaling molecules to direct adaptive responses in a microbe-specific manner.  
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In particular, macrophages and DCs play important roles in PRR recognition of 
C. albicans and serve as antigen presenting cells, linking innate and adaptive 
immunity.   
Neutrophils are potent antifungal cells and play a key role in the 
prevention of fungal growth and the invasion of tissues. Defects in neutrophil 
number and function have been consistently implicated in the pathogenesis of 
disseminated candidiasis [92, 93].   In particular, defects in oxidative defenses of 
neutrophils such as myeloperoxidase (MPO) or NADPH oxidase increase 
susceptibility to systemic infection [94, 95].  C. albicans first encounters 
neutrophils in the bloodstream during systemic infection. Neutrophils inhibit C. 
albicans growth, enhance the fungal response to overcome nitrogen and 
carbohydrate starvation, and induce the expression of a large number of genes 
involved in the oxidative stress response [93].  In addition, neutrophils are the 
primary antifungal cell recruited to the site of tissue infection. Studies have 
demonstrated that TNF-α, IL-6, and G-CSF play an important role in the 
recruitment of PMNs at the site of invasive Candida infection [96-98].   In the 
absence of either TNFα or IL-6, the course of experimental disseminated 
candidiasis is more severe, due to defective PMN recruitment  [99].  Treatment of 
mice with recombinant G-CSF (rG-CSF) leads to a significantly reduced mortality 
and fungal burden during disseminated candidiasis [100].  This is likely due to the 
ability of this cytokine to promote proliferation and differentiation of neutrophils 
from bone marrow.  In terms of chronic infections, the role of neutrophils may be 
primarily as a source of pro-inflammatory cytokines, since these cells have been 
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shown to produce TNFα, IL-6 and IL-12 upon stimulation with virulent Candida 
strains, but not avirulent, hyphal defective mutants strains[97]. 
Macrophages also play an essential role during systemic candidiasis.  In 
an experimental model of systemic candidiasis, macrophage depletion resulted in 
delayed clearance and high kidney fungal burden [101]. Macrophages can kill 
Candida via oxygen-dependent or independent pathway [102]. Oxygen 
dependent pathways include production of both reactive oxygen and nitrogen 
intermediates (ROI, RNI).  In particular, nitric oxide (NO) has strong antifungal 
activity; however, C. albicans can evade host defense by suppression of 
NO/superoxide radical production by stimulated macrophages [103-105]. 
Furthermore, what were thought to be two independent pathways, i.e., nitric 
oxide and superoxide anion, have now been shown to combine to form a potent 
macrophage candidacidal molecule, peroxynitrite. Oxygen independent pathways 
are less well studied.  However, upon phagocytosis of C. albicans, yeast forms 
can germinate and lyse macrophages [106].  Therefore, whether the macrophage 
or the fungus prevails is dependent on several factors, including the type of 
macrophage and activation state.  In contrast to neutrophils, which are important 
in resistance to early stages of C. albicans infections, differentiated macrophages 
activated by cytokines such as IFN-γ participate in the acquired resistance of 
hosts with C. albicans-specific, cell-mediated immunity.   
DCs are one of the most potent antigen presenting cells and has the 
potential to educate the naïve T cells to further induce adaptive immune 
responses. DCs arise from the bone marrow progenitor cells called common DC 
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precursors and migrate via blood to both primary and secondary lymphoid 
tissues as well as peripheral tissues (mucosal surfaces, skin).  Immature DCs are 
characterized by their low endocytic activity and inability to educate naïve T-cells. 
Upon phagocytosing antigens or pathogens, they are activated to become 
mature DCs, which express activation markers CD80 and CD86, co-stimulatory 
molecules B7.1 and B7.2, as well as high levels of MHC class I and class II 
molecules.  Activated mature DCs then migrate to the regional lymph nodes via 
the afferent lymphatic vessels where they lose the ability to further uptake 
antigen.  Mature DCs secrete immune signaling compounds and interact with 
naïve T cells and influence differentiation of different T cell subsets. 
 There are two main subsets of DCs defined by cellular lineage markers: 
classical or myeloid type DCs (CD11c+ CD11b+), and plasmacytoid DCs (CD11c+ 
B220+).  Myeloid DCs (mDCs) are the typical DCs displaying dendritic extensions 
and having antigen-presentation function in steady-state [107].  Also known as 
lymphoid organ-resident DCs, mDCs are derived from blood-borne progenitors 
and are found in the thymus, spleen, and lymph nodes, where their actions are 
restricted to the organ in which they reside. In addition, mDCs are more prevalant 
in the body and are found in the regions like mucosal linings and skin tissue [63, 
108-110]. Plasmacytoid DCs (pDCs) lack dendrites but have a plasmacytoid 
shape. Unlike mDCs, pDCs are very thinly distributed in the body and they 
normally reside in lymph nodes, blood and thymus. Signaling via various 
molecules cause their recruitment at the site of infection. pDCs express lower 
levels of MHC class II and are much less efficient at inducing T-cell proliferation 
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compared with mDCs [111].  Mature DCs educate the naive T cells into Th1, 
Th2, Th17 or Treg phenotype [112, 113]. In terms of Candida systemic infection, 
a Th1 response results in protection and clearance, while a Th2 response is non-
protective [114]. Th1 responses require production of phagocyte activating pro-
inflammatory cytokines such as IFN-γ IL-12, IL-6, and TNF-α [74, 115-118].  
Tregs or Th3 cells have potent anti-inflammatory activities and aid both 
controlling inflammation and in resolution of inflammation after infection [119, 
120]. Tregs are involved in suppressing inflammation and promoting tolerance 
via contact dependent and independent mechanisms.  In particular, they are 
associated with secretion of anti-inflammatory cytokines IL-10 and TGF-β [56].  
There are several subsets of Tregs: CD4+CD25+ intrinsic Tregs, and Tregs 
induced in the periphery. The majority of the time C. albicans exists as a 
commensal, not a pathogen.  In this situation, it would benefit the host not to elicit 
an inflammatory immune response, but instead maintain tolerance via generation 
of Tregs. However, Tregs could exacerbate disease by dampening protective 
inflammatory responses in the case of systemic infection [121]. Therefore, 
dendritic cells and other antigen presenting cells must be able to quickly 
discriminate between commensal and pathogenic Candida growth states and 
initiate the proper T cell-mediated response. 
 Th17 cells have a distinct lineage and cytokine profile compared with Th1 
and Th2 cells.  Naïve T cells differentiate into Th17 cells in the presence of a 
combination of TGF-β, IL-6, IL-1, and IL-21, while IL-23 is essential for Th17 cell 
expansion and function. Th17 cells secrete a unique profile of cytokines including 
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IL-17 (IL-17A), IL-17F, IL-21, IL-22 [66].  Production of these cytokines induces 
neutrophil activating factors, antimicrobial peptides, and acute response proteins 
(reviewed in [122]).  In terms of systemic candidiasis, the Th17 response is 
required for protection as mice lacking IL-17 receptor are more susceptible to 
acute intravenous infection [123, 124].  This was associated with reduced 
neutrophil recruitment.  In addition, vaccination with a hyphal adhesin protein 
induced a protective Th17 response and Th17 cells enhanced phagocytic killing 
of C. albicans in vitro [125].   
DCs have the ability to distinguish and discriminate between the two 
different Candida morphotypes, i.e., hyphae and yeast form. Coordinated 
signaling via TLRs results in either pro or anti-inflammatory responses by 
production of different cytokines which will cause changes in downstream 
signaling molecules to influence adaptive immune responses [126].  Recognition 
of DCs with yeast form of Candida results in stimulation of type 1 cytokines 
(DC1).  This type of interaction involves signaling via TLR4 complexes.  Hyphal 
form of Candida signals via TLR2 and cause induction of type 2 cytokines (DC2).  
Other studies have indicated that interaction with hyphal forms inhibits the 
maturation followed by activation of DCs [126-128].  Studies by Graaf et al 
demonstrated that when C. albicans-pulsed DCs were injected into the mice, the 
yeast-pulsed DCs caused a protective response whereas the mice which were 
injected with hyphae-pulsed DCs lead to a non-protective response [127].   
Further, recent studies have demonstrated that C. albicans signaling via 
TLR2 induces production of host PGE2, which can cause inhibition of innate 
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responses for antifungal defenses [127].  This indicates that eicosanoids shift the 
immune response towards that of a non-protective type.  Prostaglandins 
produced by both host and fungal cells also enhance morphogenesis in C. 
albicans suggesting that eicosanoids could participate in modulating the immune 
responses by both influencing Candida and DC biology [77, 129].  Thus, 
depending on the morphotypes of Candida (yeast or hyphal form), the DCs have 
the ability to modulate the immune responses. 
  
Immunoregulation by Eicosanoids 
 
Host eicosanoid production.  
Eicosanoids are one of the most abundant subfamily of oxylipins, which 
are oxidized fatty acids [47].  Eicosanoids are made up of 20 carbon PUFA 
metabolites that include the prostaglandins (PGs) and leukotrienes (LTs).  
Eicosanoids, whose major precursor is arachidonic acid, potent modulators of 
immune responses [130, 131].  Eicosanoids can be divided into various 
subfamilies, the main one being prostanoids which are products of a 
cyclooxygenase (COX).  Various subfamilies of the prostanoids are differentiated 
based on the region of the oxygen substitution in the cyclopentane ring, and also 
by a number, representing the number of cis double bonds in the lipids [132].  
For example, a prostaglandin of the E class derived from arachidonic acid will be 
denoted as prostaglandin E2 (PGE2).  
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 The polyunsaturated fatty acids are sequestered in membrane 
phospholipids and are released upon receiving various endogenous or 
exogenous signals.  Upon the release of precursor fatty acids from the 
membrane, they are re-esterified or enzymatically converted to eicosanoids.  
These eicosanoids generally have a very short half-life as they are immediately 
hydrolysed or undergo spontaneous metabolic inactivation, which could take 
place by the process of ω-hydroxylation, fatty acid β-oxidation and enzymatic 
dehydrogenation.  As a result of these processes, eicosanoids are generally not 
stored in the cells.  During the initial steps in biosynthesis of eicosanoids, 20 
carbon PUFA precursor (generally arachidonic acid) are released from the 
membrane phospholipids by the action of an enzyme called phospholipase 
(specifically phospholipase synthases A2 in mammalian cells) [131].  The initial 
step of prostaglandin biosynthesis is catalysed by COX (also known as 
prostaglandin H synthase) which are bifunctional heme-dependent enzymes  
[133].  In mammals, there are two COX enzymes, COX-1 being constitutive form 
and COX-2 being inducible form [131]. These enzymes are inhibited by a class of 
drugs known as NSAIDs (non-steroidal anti-inflammatory drugs), which includes 
aspirin, indomethacin, etc.  The different classes of prostaglandins are then 
synthesized by specific synthases and hydrolases.   
PGE2 is one of the most well studied prostaglandins and is a pleiotropic 
signaling molecule. PGE2 signals via four receptors on host cells: EP1, EP2, 
EP3, and EP4 [134].  In terms of immune regulation during infection, PGE2 is 
associated with anti-inflammatory activities such as inhibition of effector functions 
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of inflammatory cells.  These include inhibition of mediator release from DCs, 
macrophages, neutrophils, mast cells, basophils and lymphocytes [135].  Studies 
have shown that PGE2 can interfere with DC maturation and cytokine secretion, 
events required for migration to T cell areas and subsequent T cell education and 
activation [46, 136, 137].  In addition, PGE2 and other eicosanoids can 
downregulate macrophage functions including phagocytosis [9, 138-140].  To 
summarize the different roles of PGE2 that it plays towards immune cell 
modulation are to suppress macrophage cytokine and chemokine secretion 
[141], inhibition of  IL-12 and IFN-γ production by NK cells [141, 142], inhibition of  
T-cell proliferation [71, 143], enhancement of  IgE class switching by B-cells 
[144], up-regulation of  antigen-induced mast cell degranulation [145], inhibition 
of  lymphocyte-endothelial cell interactions etc.  
Eicosanoid production by host cells can also be influenced by the 
interaction with fungal pathogens.  C. albicans induces activation of COX-2 
transcription and the production of host PGE2 synthesis in macrophages, 
splenocytes, and endothelial cells [146-148]. The ability to control or clear 
Candida infection is dependent on the intensity of the inflammatory response 
(Th1 vs Th2).  Excess of PGE2 is shown to be associated with prevention of 
synthesis of TNF-α and IL-12 and aids in the release of Th2 attracting cytokines 
like IL-10.  IL-10 is an important cytokine in regulating immune response and 
plays key role in maintaining DCs in an immature state [72, 149]. Recent studies 
have indicated an increased level of PGE2 production from the vaginal lavage 
fluids from recurrent vulvovaginal patients [150]. This suggests that fungal 
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manipulation of host eicosanoid production may be one strategy the organism 
uses to subvert the immune system. 
 
Candida eicosanoid production 
The potential for eicosanoid production in medically important fungi had 
been overlooked until recently.  C. albicans causes release of arachidonic acid 
from host tissues, which could be used for eicosanoids production [149, 151].  
Candida produces both endogenous oxylipins as well as novel eicosanoid 
products from exogenous arachidonic acid [77, 148].  A novel eicosanoid product 
was detected, 3,18-diHETE, which is related to the 3-HETE product detected in 
the lipomycetaceous fungi.  By immunofluorescence, endogenous eicosanoid 
products were found in hyphae, but not in yeast forms, suggesting that this 
product may be involved in morphogenesis.  The production of this novel 
eicosanoid could be inhibited by aspirin, which also suppressed the growth of the 
yeast form and prevented the yeast to hyphal transition of C. albicans [152]. 
 A fungal oxylipin was isolated from Candida that exhibits cross-reactivity 
with host PGE2. This compound, termed PGEx, is bioactive on mammalian cells 
in vitro similar to PGE2, indicating the fungal oxylipins can modulate host immune 
responses [77]. Fungal PGEx inhibited chemokine production, TNF- production, 
and splenocyte proliferation while up-regulating IL-10 production.  In terms of 
effects on C. albicans, host PGE2 and fungal PGEx enhance C. albicans 
morphogenesis, and up-regulated hyphal specific genes [77, 129].  Candida 
oxylipin production is also upregulated during biofilm formation [153].   
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C. albicans does not possess arachidonic acid when grown in vitro.  
Therefore endogenous PGEx must be structurally distinct from host PGE2.  
Because PGEx works similar to PGE2, it is likely that the ring group which is 
recognized by EP receptors is similar, but the overall carbon length in shorter.  
However, supplementation of C. albicans cultures with exogenous arachidonic 
acid significantly increases PGEx production [154].  Therefore, PGEx derived 
from arachidonic acid was analyzed to determine whether it is authentic PGE2.  
Analysis of PGEx using LC-MS/MS determined that it possesses an identical 
mass and elution time as commercial PGE2 standard.  Further analysis using 
MS/MS revealed that the fragmentation pattern for the PGEx and PGE2 standard 
were identical [155].  This study was indicative of the fact that C. albicans can 
synthesize authentic PGE2.  Hence, C. albicans can synthesize both endogenous 
PGEx and PGE2 from exogenous archidonic acid. In terms of levels of 
production, in the presence of arachidonic acid, 99% of PGEx is PGE2.  
Treatment of C. albicans with various COX inhibitors decreases fungal 
prostaglandin production [156].  In vitro studies have also demonstrated that 
COX inhibitors (aspirin, etodolac, diclofenac, celecoxib, nimesulide, ibuprofen, 
and meloxicam) inhibit morphogenesis and biofilm formation [157].  In addition 
aspirin reduces damage to host cells infected with Candida by inhibiting 
extracellular fungal lipases [158]. Unlike mammalian eicosanoid production, little 
is known about the genes involved in the pathway during prostaglandin formation 
in fungi. This is due largely to differences between fungal and mammalian 
enzymes at both the nucleic and amino acid sequence level. It was found that a 
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C. albicans fatty acid desaturase homolog (Ole2) and a multicopper oxidase 
homolog (Fet3) play roles in prostaglandin production, with mutant strains 
exhibiting reduced PGE2 levels compared with parent strains.   
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CHAPTER 1 
Effect of PGEx and PGE2 on C. albicans Interactions 
with Dendritic Cells in Vitro and In Vivo 
ABSTRACT 
 Candida albicans produces an immunomodulatory oxylipin from 
arachidonic acid that is structurally identical to host prostaglandin E2 (PGE2), 
called PGEx.  In terms of host immune responses, PGE2 can promote Th2 
responses, which are non-protective against fungal infection.  Dendritic cells 
(DCs) are potent antigen presenting cells and reside at mucosal and lymphoid 
tissues and play an integral role in directing adaptive cell mediated immune 
responses.   We investigated the effect of PGE2 and PGEx on DC maturation 
and cytokine production at early and late time points in a DC cell line and with 
murine bone marrow derived DCs.  The ability of stimulated DCs to drive 
adaptive responses against systemic C. albicans infection was tested by DC 
vaccination.  In the presence of hyphae, PGE2 promoted early Th2 cytokine 
production (2h) as well as increased levels of maturation marker CD86 on the DC 
cell surface at 18 h.  Both PGE2 and PGEx suppressed Th1 cytokine and 
production at 18 h.  The only notable difference between yeast and hyphae 
pulsed DCs was in host cell PGE2 production.  Vaccination with yeast-pulsed 
DCs but not hyphae pulsed DCs lead to protective against systemic infection, 
with reduced fungal burden in the kidneys.  However, treatment with either PGEx 
or PGE2 abrogated the ability of yeast pulsed DCs to induce protection.  The lack 
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of protection was associated with inhibition of Th1 cytokines and increased Th2 
cytokines in the spleen.  Locally, exacerbated Th2 and Th17 cytokines were 
detected in the kidneys of mice that were not protected against systemic 
infection.  This indicates that host PGE2 or fungal PGEx can shift adaptive 
responses in favor of the pathogen and that uncontrolled Th17 responses are 
detrimental during systemic infection. 
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INTRODUCTION 
 
Candida albicans poses a significant clinical threat to both 
immunocompetent and immunocompromised individuals.  Chronic colonization at 
mucosal surfaces with Candida is common, with carriage rates among healthy 
adults ranging from 30-70% [2, 3]. Mechanisms by which Candida persists at 
mucosal surfaces in the face of an adaptive immune response are relatively 
unknown.  Mucosal persistence can lead to infection, with the severity of 
Candida-associated diseases ranging from superficial mycoses to systemic 
candidiasis. Systemic infections are very difficult to treat and account for 40% of 
crude mortality rate [159]. 
  C. albicans produce immunomodulatory bioactive lipids (oxylipins) that 
are functionally similar to host eicosanoids, potent regulators of immune 
responses [156, 160]. Candida produces both endogenous oxylipins as well as 
novel eicosanoid products from exogenous arachidonic acid [156, 161].  A fungal 
oxylipin was isolated from Candida that exhibits cross-reactivity with host PGE2.  
This compound, termed PGEx, is bioactive on mammalian cells in vitro similar to 
PGE2, indicating the fungal oxylipins can modulate host immune responses 
[156].  Noverr et. al. reported that host PGE2 and fungal PGEx enhance C. 
albicans morphogenesis [156, 162].  Candida oxylipin production is also 
upregulated during biofilm formation [157].  Analysis of PGEx using LC-MS/MS 
determined that it possesses an identical mass and elution time as commercial 
PGE2 standard.  Further analysis using MS/MS revealed that the fragmentation 
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pattern for the PGEx and PGE2 standard were identical [154].  This study was 
indicative of the fact that C. albicans has the potential to synthesize authentic 
PGE2.  Hence, C. albicans can synthesize both endogenous PGEx and PGE2 
from exogenous arachidonic acid. The fact that both the host and yeast can 
produce similar immunomodulatory signaling molecules suggests that host and 
pathogen can participate in cross-species communication.  Further, oxylipins 
may enable Candida to modulate immune responses in favor of persistence and 
infection.  The role of Candida oxylipins in host-pathogen interactions and 
Candida biology is not understood, nor have the biosynthetic pathways been 
elucidated.  
 Dendritic cells (DCs) are one of the first types of immune system cells to 
interact with C. albicans at the mucosal surface. The role of dendritic cells is to 
discriminate between different types of microbes and direct appropriate immune 
responses, linking innate and adaptive responses.  Two types of DCs -myeloid 
DC (mDC) and plasmacytoid DC (pDC) have been characterized and have 
distinct origins and functions.  Studies have depicted that plasmacytoid DCs 
(CD11c+ B220+) have been more involved with regulation of immunity and 
tolerance of induction.  On the other hand myeloid DCs  (CD11c+ B220−) are 
involved in the elevation of  inflammatory responses [163] .  DCs have the ability 
to distinguish and discriminate between the two different Candida morphotypes, 
i.e., hyphae and yeast form.    Coordinated signaling via TLRs results in either 
pro or anti-inflammatory responses by production of different cytokines which will 
cause changes in downstream signaling molecules to influence adaptive immune 
 
 30
responses [164].  Recognition of DCs with yeast form of Candida results in 
stimulation of type 1 cytokines (DC1).  This type of interaction involves signaling 
via TLR4 complexes.  Hyphal form of Candida signals via TLR2 and cause 
induction of type 2 cytokines (DC2). Studies by Graaf et al demonstrated that 
when candida-pulsed DCs were injected into the mice, the yeast pulsed DCs 
caused protective response whereas the mice which were injected with hyphae-
pulsed DCs lead to a non-protective response [80]. DCs have the potential to 
initiate specific T cell responses after interacting with pathogens. In terms of 
Candida infection, a Th1 response results in protection and clearance, while a 
Th2 response is non-protective, leading to disease [114]. Therefore, depending 
on the type or nature of fungal morphology, i.e., yeast or hyphal form, the DCs 
can regulate the T cell immunity caused by C. albicans during commensalism or 
persistent infection, respectively.   
 PGE2 is a pleiotropic immune signaling compound and has effects on a 
variety of cell types, including DCs.  Exposure of DCs to PGE2 leads to inhibition 
of type I cytokines (TNF-α and IL-12) and promotes release of type II cytokines 
(IL-10) [36, 37].  Studies have shown that PGE2 can interfere with DCs 
maturation and cytokine secretion, events required for migration to T cell areas 
and subsequent T helper cell education and activation [165-167]. Thus, PGE2 
may play role in promoting a non-protective immune response towards fungal 
infection.  The aim of our studies is to understand the effects of PGE2 and PGEx 
on DC maturation and differentiation, and how these effects influence adaptive 
immune responses during infection.   
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MATERIALS AND METHODS 
 
Mice.  Female retired breeders or 6-8 week old mice of C57BL/6 strain were 
obtained from Charles River Laboratories (Wilmington, MA). All mice were 
maintained at an American Association for the Accreditation of Laboratory Animal 
Care-accredited animal facility at Wayne State University (WSU) and housed in a 
pathogen-free environment in accordance with the procedures outlined in the 
Guide for the Care and Use of Laboratory Animals under an animal study 
proposal approved by the WSU animal investigation committee. 
 
C. albicans Strains and Culture Conditions.  The C. albicans strain SC5314 
used in this study is a prototrophic parental strain [168]. This strain was 
subcultured from frozen stocks and grown overnight at 30°C in Sabouraud 
dextrose agar (SDA) (Becton, Dickinson and Company, Sparks, MD).  For liquid 
cultures, isolated colonies from the SDA plates were cultured in Sabouraud 
dextrose broth (SDB) with constant shaking.  To obtain hyphal form, yeast form 
of C. albicans was added to RPMI supplemented with 10% FBS at the 
concentration of 1 x 106 Candida per ml of media.  Hyphae were generated after 
2 h incubation at 37°C. 
 
JAWSII Cell line and Culture conditions.  An immature dendritic cell line called 
JAWSII (ATCC CRL-11904) was used for the purpose.  It is a GM-CSF 
dependent dendritic cell line derived from the bone marrow of C57BL/6 mice 
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[169-171].  The frozen vial containing the cells were thawed rapidly 
(approximately 2 minutes) by gentle agitation in a 37°C water bath.  After 
decontaminating the surface of the vial with 70% ethanol, the vial contents were 
centrifuged at 130xg for 5 to 7 minutes.  Following this the pellet was re-
suspended with complete RPMI medium (Invitrogen) supplemented with 20% 
fetal bovine serum and 5 ng/ml murine GM-CSF in a 25 cm2 tissue culture flask.  
The cells, upon reaching a confluency of 80-90%, were subcultivated at 1:2 ratio 
by transferring the floating cells by pipetting.  Additionally, the attached cells were 
removed by rinsing with 0.25% (W/V) Trypsin-0.53mM EDTA solution followed by 
an incubation period of 5-7 minutes at 37°C incubator.  All the cells were pooled 
and centrifuged at 125 xg for 5 to 10 minutes.  After discarding the supernatant, 
the pellet was resuspended in fresh medium and transferred into a fresh new 
flask.  Following this, the flask was incubated at 37°C incubator in a 5% CO2 in 
air atmosphere.  Since these are very slowly growing cell line, the medium was 
renewed at an interval of one time per week. 
 
JAWSII Antigenic Stimulation and Harvest.  The JAWS II cells were seeded in 
six-well plates, each well at the concentration of 5 x 106 per well.  They were than 
stimulated with 1µM of PGE2 (Cayman Chemicals, Ann Arbor).  An hour after 
incubation, the cells were further stimulated with yeast or hyphae in presence 
and absence of this prostaglandin at a MOI of 1.  The control well was stimulated 
with only PGE2.  After an incubation period of 2 hrs Amphotericin B was added at 
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a final concentration of 2.5 µg/ml.  Further, the cells were trypsinized from the 
surface using trypsin-EDTA in order to perform RNA extraction from them. 
 
Oligo GEArray DNA Microarray.  RNA was extracted from the antigen pulsed 
JAWSII cells using RNeasy mini kit (Qiagen).  A fraction of this RNA sample was 
run on denaturing agarose gel to verify any possibility of degradation by looking 
at the 18s and 28s ribosomal bands.  A total of 0.1-3 µg RNA was used as a 
starting material from which cDNA was synthesized using TrueLabeling primer 
(Superarray Bioscience Corporation).  Following this cRNA synthesis, labeling, 
amplification and purification was performed using manufacturer’s provided kit.  
Further, the biotin-labeled amplified cRNA was hybridized on a prehybridized (the 
membrane was pre-wet in deionized water followed by replacing it with GEAhyb 
hybridization solution and rotating the tube in oven for up to 72 hours) array 
membrane inside a 5 ml disposable screw-top Hybtubes.  At least 2 µg of biotin-
labeled cRNA was added into the target hybridization mix. The hybridization step 
was performed overnight inside a roller-bottle hybridization oven at 60°C with 
continuous but agitation at 5 to 10 rpm.  After hybridization steps, a series of 
washing steps were performed mostly using various concentrations of SSC and 
SDS solution.  After washing, chemiluminescent substrate was added to the 
hybridization tube and rotated inside hybridization oven allowing the membrane 
to incubate with the CDP-star for a brief period (2-5min).  For image acquisition, 
a CCD camera was used with an exposure period of 16 minutes and all the 
images were saved as electronic files in a gray scale in 8 or 16 bit TIFF format.  
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For data analysis of the arrays, an integrated web-based GEArray expression 
analysis suite software was used.  A two-fold value increase or higher compared 
to the control was considered as significant increase.  
 
Primer Design.  The gene specific  primers for mouse IL-4, IL-6, IL-10, IL-12 and 
GAPDH used for RT qPCR (SABiosciences).  These were experimentally verified 
for their efficiency.  The catalog number for IL-4 is PPM03013E, IL-6 is 
PPM03015A, IL-10 is PPM03017B, IL-12 is PPM03020E and GAPDH is 
PPM02946E. 
 
qRT-PCR Assay.  qRT-PCR assay was performed using a MyiQ  thermocycler 
(Bio-Rad, Hercules, CA, USA).  Each well contained a 25-µl reaction mixture that 
included 12.5µL of 2× SYBR Green PCR Master Mix (Bio-Rad,), 1µl of gene 
specific 10µM each of forward and reverse primers, 1µL of DNA template at 
convenient dilution. The following thermocycling pattern was used: 95 °C for 
10 min (to activate the hot start DNA polymerase; 95 °C for 15 s, 60 °C for 1 min 
(40 cycles).  A melting-curve analysis was performed at the end of each PCR 
assay to control that a single PCR-product was amplified.  qRT-PCR was carried 
out on appropriate DNA dilutions in triplicate.  For normalization, the mRNA for 
mouse GAPDH was quantified in parallel for all other samples.  For data 
analysis, difference between the critical threshold Ct values (ΔCt) for each 
cytokine gene and the housekeeping gene was calculated.  The ΔΔCt was 
obtained from the difference in the ΔCt values between the experimental and 
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control genes.  The fold change in CT between the cytokine gene expression 
from the antigen pulsed dendritic cells and the change over unstimulated 
dendritic cells was determined using the 2−ΔΔCt method [172].  
 
Purification and Culture of Bone Marrow Dendritic Cells.  Bone marrow cells 
were obtained by flushing the femurs of the mice with RPMI supplemented with 
10% FBS (Invitrogen).   The cells were then incubated with RBC lysis buffer for 2 
min followed by adding D-PBS.  Following this, the cells were centrifuged at 1000 
rpm and resuspended in complete RPMI (cRPMI) containing 5 mM HEPES 
buffer, 0.3 mg/ml L-glutamine, 5.5 X 10-5 mol/L ß-mercaptoethanol, 100 U/ml 
penicillin, 100 ug/ml streptomycin and 10% FBS. 
For obtaining the plasmacytoid DCs (pDCs), the cells were resuspended 
at the concentration of 106 cells/ml in complete medium supplemented with 200 
ng/ml recombinant murine Fms-related tyrosine kinase-3 ligand (FLT-3) 
(Prospec-Tany Tecnogene Ltd, Rehovot, Israel).  After incubation of 9 days, the 
cells were collected by removing the adherent and non-adherent cells by 
vigorous pipetting with room temperature D-PBS [173]. 
For generating the myeloid or conventional type of dendritic cells, the 
bone marrow cells were resuspended in complete RPMI at concentration of 1 X 
106 cells/ ml and stored in 37°C, 5% CO2 incubator.  On day 1, the non-adherent 
cells were removed and resuspended at concentration of 5 x 105 / ml with RPMI 
containing 20 ng/ml GM-CSF (Prospec-Tany Technogene Ltd, Rehovot, Israel) 
and 20 ng/ml IL-4 (Shenandoah Biotechnology).  Additional media and 40 ng/ml 
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of each cytokines were added on day 3.  On day 6, the cells were harvested, 
pelleted and again resuspnded in 30 ml of cRPMI supplemented with 10 ng/ml 
GM-CSF and 10 ng/ml IL-4. On day 8, the non-adherent cells were harvested 
and used in experiments [174] 
 
Flow Cytometry.  For phenotypic analysis of DC subsets, surface markers were 
analyzed using flow cytometry.  The DC were washed three times in 200 µl cold 
FACS buffer containing1% BSA / PBS, pH 7.2, 0.1% NaN3.  For purpose of 
blocking Fcγ receptors, the cells were incubated in FACS buffer containing 5% 
mice serum for 15 minutes at 4C.  For staining, cell were washed three times 
and resuspended at a concentration of 1 × 106 cells/ml in cold FACS buffer.  
Cells were stained for 30 min at 4C in dark. Cells were stained with following 
FITC or PE conjugated anti-mouse antibodies according to the manufacturer’s 
instructions: CD86 (maturation marker), CD11b, CD11c, and B220 (ebioscience).   
Myeloid DCs are CD11b+ CD11c+ and plasmacytoid DCs are B220+ CD11clo 
CD11b-. Cells were washed twice with FA buffer and were then fixed with 4% 
formalin.  FITC- and PE-conjugated antibodies used for direct staining obtained 
from ebiosciences are listed in  
Table 1.  A minimum of 20,000 events was acquired for each sample with a 
FACScan flow cytometer (BD) and analysed using Flowjo software. 
 
Isolation of fungal PGEx.  C. albicans strain SC5314 was grown overnight at 
37C in 10 ml RPMI containing 100 mM arachidonic acid.  Culture supernatants 
 
 37
were loaded onto a PGE2 affinity column (Caymen Chemical), washed, and 
eluted according to the manufacturers’ instructions.  The eluates were dried 
under a stream of nitrogen gas and resuspended in 500 µl PBS. PGEx 
concentrations (approximately 20ng) determined using a PGE2 monoclonal 
ELISA (Cayman Chemical, Ann Arbor).  
 
Pulsing of DCs and culture of cells.  DCs were harvested and washed twice in 
sterile 1x PBS, counted, and resuspended in a final concentration of 1x106 
cells/ml.  Cells were plated into 6 well tissue culture treated plates in a volume of 
6x106 cells/6ml/well.  For pulsing, DC were exposed to unopsonized yeast or 
hyphae at a DC:fungal cell ratio of 1:2.  PGE2 (Caymen Chemical) or C. albicans 
PGEx was added at a final concentration of 2nM.  After 2 h incubation, 2.5 g/ml 
amphotericin B was added to prevent fungal overgrowth.  After pulsing, cells 
were left for an additional 18 h in culture.  Supernatants were harvested for 
analysis of immune mediators.  Cells were washed and harvested for adoptive 
transfer experiments. 
 
Enzyme Linked Immunosorbent Assay.  Cell culture supernatants (DCs and 
splenocyotes) were analyzed for the following cytokines by ELISA:  IL-4, IL-5, IL-
6, IL-10, IL-12, IL-13, IFN-γ, TGF-β, TNF-α, IL-23.  The detection limits  (pg/ml) 
for the assays were <3.90 for IL-4,  < 3.90 for IL-5,  <3.90 for IL-6,  < 31.25 for IL-
10, <15.62 for IL-12, <3.90  for IL-13,  < 15.62  for  IFN-γ, <62.5 for TGF-β, <7.81 
for TNF-α and <7.81 for IL-23 (eBioscience).  In addition, DC supernantants were 
 
 38
also tested to analyze the levels of PGE2 (Cayman chemicals). The absorbance 
of the plates was measured at 450nm using Multiskan Ex microplate reader 
(Thermo Electron Corporation) and analyzed with Ascent Software. 
 
Adoptive Immunization and Fungal Challenge.  Pulsed and unpulsed BMDCs 
were trypsinized and washed with 1x sterile PBS pH 7.4 at 1000 rpm.   They 
were counted using a hemocytometer and intraperitoneally injected into the mice 
at a concentration of 5 X 105 cells per mouse in 100 µl of sterile non-pyrogenic 
PBS (Invitrogen) using a 27-gauge feeding needle attached to a 1-ml syringe.  
Mice received either a single vaccination at day 0 or a double vaccination at days 
0 and 7.  Four mice were used for adoptive transfer per each group.  7 d 
following the last adoptive transfer of BMDCs, the mice were challenged by 
intravenous tail injection with C. albicans at the concentration of 2.5 X 105 
CFU/mouse in 250 µl of sterile PBS using a 30-gauge feeding needle attached to 
a 1-ml syringe. Upon assessment of weight analysis for the purpose of 
determining any incidence of cachexia, there was no significant decrease or 
change in weights of the mice post systemic challenge with Candida for a period 
of 7 days. 
 
CFU Assay.  To determine the amount of fungal growth in the organs of the 
mice, the kidney and the liver were weighed and homogenized using a tissue 
tearor.   Serial dilutions of tissue homogenates were made in sterile water and 
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were plated onto sabouraud dextrose agar to determine the CFU per gram per 
organ in each group of mice. 
 
Splenocyte Harvest and Pulsing.  Spleens were excised from the C. albicans 
infected mice and the splenocytes were isolated from them.  A 1:1 ratio of  both 
yeast and hyphal forms of C. albicans were used at MOI 1:2 to stimulate the 
splenocytes.  After 2 h of incubation, 2.5 µg/ml of amphotericin B was added to 
prevent Candida overgrowth followed by further incubation of 16 h at 37°C, 5% 
CO2 incubator.  The supernatants were collected and the levels of cytokines 
were measured by ELISA. 
 
Histological Analysis and Immunohistochemistry.  Part of the organs (kidney 
and liver) were excised and stored immediately in 10% buffered formalin for the 
purpose of histology.  Paraffin-embedded tissues of about 3-4 nm width were 
stained with periodic acid-Schiff reagent and examined [149].  5µm sections were 
cut from paraffin-embedded kidney tissue blocks.  Antibodies used along with 
their respective companies purchased from and the dilution used are listed in   
Table 2.  For heat mediated antigen retrieval, sections were treated with for 20 
min with 10mM sodium citrate buffer, 0.05% Tween 20, pH6.0.  Incubation with 
primary antibody was performed overnight at 4°C whereas incubation with the 
biotin conjugated secondary antibody was performed for 30 min at room 
temperature.  To verify staining specificity, negative control slides or appropriate 
isotype controls antibodies and at the same dilution as that of respective primary 
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monoclonal antibodies were used.    These isotype controls used were rat IgG, 
IgM, IgG2b and IgG2a.   Samples were analyzed by light microscopy using 
Olympus BX41 microscope and Qcolor3 software tool. 
  
 Statistical Analysis.  The Student’s t test (two-tailed, unequal variance) was 
used to analyze the significance of differences between two experimental groups.  
Significance was considered with a P < 0.05 or less.  The data recorded are 
representative of either two or three independent experiments. 
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 Name of Antibody Clone                Dilution  
1. Anti-mouse CD11b                      RMMG-1 1:150               
2. Anti-mouse CD86 (B7.2)             GL1   1:160               
3. Anti-mouse CD45R (B220)          RA3-6B2           1:200               
4. Anti-mouse CD11c                      N418                1:100      
 
Table 1.  List of antibodies and dilutions used for flow cytometry.  All 
antibodies were purchased from eBioscience. 
 
 
 Name of Antibody Dilution       Company  
1. IFN-γ (clone RMMG-1) 1:400  Abcam Inc., Cambridge, MA 
2. IL-4 (clone 11B11)             1:100 Abcam Inc., Cambridge, MA 
3. IL-6  (clone )          1:400           Abcam Inc., Cambridge, MA 
4. IL-10 (clone NYRmIL-10)         1:200          Santa Cruz Biotechnology, Inc 
5. IL-12A p35 (clone M-19) 1:200           Santa Cruz Biotechnology, Inc 
6. IL-17 (clone 400210) 1:150           R & D Systems, Inc. 
7. IL-23 (polyclonal) 1:200         Santa Cruz Biotechnology, Inc 
8. Neutrophil (clone NIMP-R14) 1:100        Santa Cruz Biotechnology, Inc 
 
Table 2.  List of antibodies and dilutions used for immunohistochemistry.   
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RESULTS 
 
 
To determine the effect of prostaglandins on antigenic stimulation of DCs, 
OligoGEarray was performed to examine early (2h) expression of cytokine 
genes.  Through a simple technique of side-by-side hybridization method, 
differential expression of the genes between the samples was compared. This 
oligoarray profiles the expression of 113 genes, including cytokines in the Th1, 
Th2, Th3 pathways, and other CD4+ T lymphocytes markers and transcriptional 
factors that regulate the expression of these cytokines.  There were also other 
functional genes involved in immune cell activation, in the Th1 and Th2 type 
immune responses, antimicrobial humoral responses, etc.   We attempted to 
analyze early cytokine expression in primary bone marrow derived DCs; 
however, the amounts of cells necessary to obtain high quality RNA precluded 
using these cells. To obtain enough RNA to perform the oligoarray analysis, we 
used an immature mouse dendritic cell line (JAWSII), which is a GM-CSF 
dependent bone marrow derived cell line from C57BL/6.  Th2 cytokines IL-4, IL-
10, and IL-13 were consistently upregulated in the presence of hyphae and 
PGE2.  In addition, pro-inflammatory cytokines IL-6 and IL-15 were upregulated 
in the presence of hyphae and PGE2 (Table 3).  On the other hand, a suppressor 
of cytokine synthesis gene (SOCS-3) which was used as a control was 
upregulated in the only PGE2 treated group.  The confirmed the metabolic activity 
of this compound during the in vitro studies.  We were further able to confirm the 
up-regulation of IL-4, IL-6, and IL-10 genes showed by the oligoarray technique 
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using qRT-PCR (Figure 1). We observed no up-regulation of IL-12, which 
indicates that up-regulated genes are not due to errors in RNA concentrations. 
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E2 Y Y + E2 H H + E2
Th2 Cytokines
IL-4 0.41 0.37 2.25 1.07 3.86
IL-10 0.67 0.64 4.02 1.05 9.18
IL-13 0.73 0.73 1.08 0.95 3.03
Pro-inflammatory Cytokines
IL-6 1.68 1.09 1.5 1.8 4.43
IL-15 0.37 0.31 1.2 0.56 3.03
Cytokine Suppressors
Socs3 11.11 2.6 1.1 1.1 1.3
Table 3. Analysis of early cytokine expression in a DC cell line.   JAWSII 
cells were at a concentration of 5 x 106 per well and stimulated with PGE2 for 1 h 
followed by pulsing with C. albicans yeast or hyphae at an MOI of 2.  After 2 h, 
RNA was extracted.  Transcript levels were analyzed using a OligoGEarray kit 
and analyzed using GEArray expression analysis suite software.  A two-fold 
value increase or higher compared to the control is depicted in the table. 
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pDC mDC
Untreated PGEx, PGE2
Untreated PGEx, PGE2
Th1 
IL-12 ++++  + 
Pro-Inflammatory
IL-6 Similar  Similar n/c
Th-17
IL-23 + n/c +++ 
Th2 
IL-4 Similar Similar
IL-10 + n/c +/-   
Table 4.  Relative expression of cytokines after stimulation of dendritic 
cells with yeast or hyphae in presence or absence of prostaglandins. 
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Figure 1.  Analysis of early cytokines by quantitative real-time PCR in 
JAWSII dendritic cell line.  JAWSII cells were at a concentration of  5 x 106 per 
well and stimulated with PGE2 for 1 h followed by  pulsing with C. albicans yeast 
or hyphae at an MOI of 2.  After 2 h, RNA was extracted and pooled together for 
each sample group.  qRT-PCR was carried out on appropriate DNA dilution in 
triplicate.  For normalization, the mRNA for mouse GAPDH  was quantified in 
parallel for all other samples.  For data analysis,  difference between the Ct 
values (ΔCt) for each cytokine gene and the housekeeping gene was calculated.  
The ΔΔCt was obtained from the difference in the ΔCt values between the 
experimental and control genes.  The fold change in critical threshold (CT) 
between the cytokine gene expression from the antigen pulsed dendritic cells 
and the change over unstimulated dendritic cells  was determined using the 
2−ΔΔCt method Data is representative of two independent experiments 
performed in triplicate. 
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To confirm the results from studies with the DC cell line extend to primary 
DC subsets, bone marrow derived plasmacytoid and myeloid type DCs were 
used in vitro studies.  There are several methods of generating DCs from bone 
marrow in vitro.  Culturing cells in the presence of GM-CSF generates myeloid or 
inflammatory DCs, while FLT3-ligand preferentially expands plasmacytoid or 
steady state DC populations [175-177].  Both types of DCs were characterized 
for cell surface marker expression by performing FACS analysis as previously 
described [178].  GM-CSF differentiated DCs (GM-DCs) were 86.3% CD11c+ 
B220- and 81.32% CD11b+ CD11c+ indicative of a myeloid DC phenotype (2a 
and b).  On the other hand, Flt-3L differentiated DCs (FL-DCs) were CD11clow 
(57.7%) compared with GM-DCs (Figure 2c).  FL-DCs showed increased 
expression of B220, with 45.7% were double positive for CD11c and B220, which 
is indicative of a plasmacytoid DCs phenotype (Figure 2d) [175]. Most of the 
remaining cells were CD11c+B220-. This is to be expected as FLT3-ligand 
generates a heterogeneous population of DCs similar to steady state splenic 
DCs.  Regardless, FL-DCs are functionally similar to plasmacytoid DCs in 
experimental models [79, 179]. Therefore, we will refer to GM-DCs as mDCs and 
FL-DCs as pDCs. 
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Figure 2.  Characterization of bone marrow derived dendritic cells. Murine 
bone marrow was harvested from C57BL/6 mice and cultured in the presence of 
GM-CSF (mDCs) or FLT3-ligand (pDCs).   A,B) Surface expression of B220, 
CD11c, and CD11b on mDCs.  C) Relative surface expression of CD11c on 
pDCs (pDC-CD11clow) and mDCs (mDC-CD11chi).  D) Surface epression of 
CD11c and B220 on pDCs.  The above data is representative of two independent 
repeats of FACS analysis. 
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 To investigate the effect of C. albicans and prostglandins to induce 
maturation of mDCs and pDCs in vitro, we analyzed CD86 expression, which is 
upregulated during antigen presentation by dendritic cells. In unpulsed mDCs 
16.3% of cells were CD11c+CD86+ and 13.3% of pDCs were B220+CD86+ 
(Figure 3). Upon stimulation of mDCs with Candida, CD86 expression increased 
to 18.9% in the presence of yeast and to 21.42% in the presence of hyphae 
(Figure 3a).  Upregulation of CD86 was more dramatic with pDCs, with increases 
from 13.3% to 36.44% with yeast and 46.8% for hyphae (Figure 3b).  Addition of 
PGE2 further increased CD86 expression in both DC types in the presence of 
both yeast and hyphae. These results demonstrate exposure of mDCs and pDCs 
to C. albicans and PGE2 induces maturation, with the greatest effects observed 
in the presence of hyphae and PGE2.  
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A) mDCs
B) pDCs
 
 
Figure 3.  Maturation marker expression on mDCs and pDCs stimulated 
with C. albicans and PGE2. Murine bone marrow was harvested from C57BL/6 
mice and cultured in the presence of GM-CSF (mDCs) or FLT3-ligand (pDCs). 
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Cells were stimulated with C .albicans strain SC5314 yeast (grown in  SDB at 
30°C) or hyphae (formed in 100% FBS at 37°C for 2h) at MOI of 2  in presence 
or absence of 2 nM PGE2. After 2 h incubation, Candida was killed by adding 2.5 
µg/ml of amphotericin B to the culture. Cells were harvested after 18 h and 
stained with A) CD11c and CD86 for mDCs and B) B220 and CD86 for pDCs.  
The isotype controls tested negative. The experiment was performed  in 
duplicate with two independent repeats with similar results. 
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 To analyze effects of PGE2 on early cytokine production in primary DCs, 
we used qRT-PCR to measure changes in cytokines identified from the 
oligoarray performed with the JAWSII cell line. Compared with yeast pulsed DCs, 
hyphal pulsed DCs also tended to have higher IL-4 and lower IL-12 expression, 
indicative of a shift towards a Th2 phenotype (Figure 4). Similar to what was 
observed previously with JAWSII cells, treatment of hyphal pulsed DCs with 
PGE2 resulted in the highest upregulation of IL-4 and IL-6, with concomitant 
decreases in IL-12. Similar results were obtained with both mDCs and pDCs.  
This indicates the PGE2 treatment can further promote pro-Th2 or pro-Th17 
responses from DCs pulsed with hyphae. 
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Figure 4.  Analysis of early cytokines by quantitative real-time PCR in 
mDCs and pDCS.   Murine bone marrow was harvested from C57BL/6 mice and 
cultured in the presence of GM-CSF (mDCs) or FLT3-ligand (pDCs). Cells were 
stimulated with C .albicans strain SC5314 yeast  or hyphae at MOI of 2  in 
presence or absence of 2 nM PGE2 or PGEx. After 2 h, RNA was extracted and 
pooled together for each sample group. qRT-PCR was carried out on appropriate 
DNA dilution in triplicate.  For normalization, the mRNA for mouse GAPDH  was 
quantified in parallel for all other samples.  For data analysis,  difference between 
the Ct values (ΔCt) for each cytokine gene and the housekeeping gene was 
calculated.  The ΔΔCt was obtained from the difference in the ΔCt values 
between the experimental and control genes.  The fold change in critical 
threshold (CT) between the cytokine gene expression from the antigen pulsed 
dendritic cells and the change over unstimulated dendritic cells  was determined 
using the 2−ΔΔCt method. Data is representative of two independent experiments 
performed in triplicate. 
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 Cytokine analysis of DC culture supernatants at a later time point (18 h) 
was performed by ELISA to monitor phenotypic differentiation of both mDCs and 
pDCs after antigenic stimulation (Figure 5). As reported previously, pDCs 
secreted higher levels of the Th1 cytokine, IL-12, compared to mDCs [79].  
Addition of either PGE2 or PGEx decreased the secretion of this cytokine in both 
DC subsets. Similarly, a trend towards decreased production of pro-inflammatory 
cytokine IL-6 was also observed in the presence of prostaglandins.  The Th2 
cytokine IL-4 showed similar cytokine secretion pattern from both types of 
dendritic cells, which was slightly increased in presence of prostaglandin.  
However, IL-10 was inhibited by prostaglandins in mDCs but slightly increased 
with pDCs. Increased levels of the Th17 cytokine, IL-23, was observed in mDCs 
as previously reported, which was inhibited in presence of prostaglandins [79]. 
The comparative summarization of cytokine induction pattern is listed in Table 3.  
Overall, the data indicate that prostaglandins dampen Th1 cytokines, which could 
result in generating a non-protective Th2 phenotype. 
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Figure 5.  Analysis of late cytokine production by ELISA in mDCs and 
pDCs. Murine bone marrow was harvested from C57BL/6 mice and cultured in 
the presence of GM-CSF (mDCs) or FLT3-ligand (pDCs). Cells were stimulated 
with C .albicans strain SC5314 yeast (grown in  SDB at 30°C) or hyphae (formed 
in 100% FBS at 37°C for 2h) at MOI of 2  in presence or absence of 2 nM PGE2 
or PGEx. After 2 h incubation, Candida was killed by adding 2.5 µg/ml of 
amphotericin B to the culture.  Cultured supernatants were harvested after 18 h 
incubation and further used to assay for cytokines by ELISA. Data is 
representative of three independent experiments performed in triplicates and 
assayed in duplicate.  * P < 0.05, prostaglandin treated vs. untreated cells.  
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Figure 5 continued 
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Table 5.   Relative expression of cytokines after stimulation of dendritic 
cells with yeast or hyphae in presence or absence of prostaglandins. 
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To determine the effects of C. albicans on prostaglandin levels in the DC 
cultures, we tested the levels of PGE2 from the culture supernatants.  PGE2 
levels were relatively low and did not significantly differ in any of the antigenic 
groups at 2 h post-pulse (Figure 6).  Because C. albicans was viable during this 
period, PGE2 could be derived from C. albicans or the DCs.  At 18 h post-chase 
we observed increased production of PGE2 from the hyphae pulsed group in both 
mDCs and pDCs (Figure 6).   This PGE2 is not produced from Candida as they 
were killed after 2h with amphotericin B treatment.  These data indicate that 
hyphae induce significant PGE2 production from DCs. 
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Figure 6.  Production of PGE2 from stimulated mDCs and pDCs.  Murine 
bone marrow was harvested from C57BL/6 mice and cultured in the presence of 
GM-CSF (mDCs) or FLT3-ligand (pDCs). Cells were stimulated with C .albicans 
strain SC5314 yeast (grown in  SDB at 30°C) or hyphae (formed in 100% FBS at 
37°C for 2h) at MOI of 2.  Supernatant was harvested at 2 or 18 h post-pulse. For 
the 18 h time point, after 2 h incubation, Candida was killed by adding 2.5 µg/ml 
of amphotericin B to the culture. PGE2 levels were measured using a monoclonal 
PGE2 EIA kit.  Experiments were performed in triplicate and assayed in duplicate 
and data is representative of two independent repeats. * P < 0.05, prostaglandin 
pulsed vs. unpulsed cells. 
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 To further investigate the functional activities of the antigen stimulated 
DCs in vivo, adoptive transfer experiments were performed. In initial 
experiments, mice received a single adoptive transfer 7 d prior to systemic 
challenge with C. albicans infection (Figure 7).  To assess protection against 
infection, kidney, blood, spleen and liver fungal burden was analyzed, which are 
the major target organ during systemic infection.  In mice vaccinated with antigen 
pulsed mDCs, no protection was observed after adoptive transfer with antigen 
pulsed cells (Figure 8a). However, the yeast pulsed pDC-vaccinated mice 
showed close to a two-fold decrease in kidney fungal burden compared to the 
other groups (Figure 8b). Interestingly, PGE2 or PGEx treatment abrogated 
protective effect of yeast pulsed pDCs during vaccination (Figure 8b). This 
indicates that mDCs do not impart the same type of protective response as 
pDCs. Cytokines from restimulated splenic cultures were analyzed to 
characterize the immune response in vaccinated mice.  We observed increased 
IL-6 production in the mice that received yeast-pulsed pDCs and decreased 
levels in all other groups (Figure 8). While this indicated that a protective pro-
inflammatory response may be elicited in yeast pulsed pDC mice, the splenic 
response was relatively weak. No significant differences in IL-12, TNF-α, IL-4, IL-
10, or TGF-β were observed, with very low levels produced (data not shown). 
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Yeast or Hyphae
+/- 2 nM PGE2 or PGEx
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Wash Cells
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0 7 14 21
DC
Harvest  
 
Figure 7.  Dendritic cell vaccination or adptive transfer strategy. The antigen 
pulsed dendritic cells were interperiteonally injected into the mice at a 
concentration of 5X105/mouse on day 1.  On day 7, this adoptive transfer with the 
pulsed dendritic cells was repeated again.  On day 14, the mice were challenges 
with systemic infection by injecting them with 2.5X105  Candida through tail vein 
injection.  On day 21, the organs (spleen, liver, kidneys, blood) were harvested 
from accessing protection. 
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Figure 8.  Assessment of protection from C. albicans infection following 
single adoptive transfer with mDCs or pDCs.  Antigen pulsed A) mDCs or B) 
pDCs were harvested after 18h of stimulation. For vaccination, 5x105  cells were 
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injected via the intraperitonial route in 6-8 week old C57BL/6 mice. After 7 d,  
mice were inoculated by tail vein injection with C. albicans strain SC5314 
(2.5x105 CFU/mouse). After 7 days post-inoculation, the mice were sacrificed, the 
kidneys excised,  homogenized and serial dilution was performed to measure 
fungal burden.  For each group, 4 mice were used.  This experiment was 
repeated four times with similar results.   DC = Dendritic cells; Y = Yeast; H = 
Hyphae. * P < 0.05 DC alone  vs. experiment groups. ** P < 0.05 treated vs. 
untreated DCs. 
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Figure 9.  Secretion of cytokines from splenic cultures of mice vaccinated 
with antigen pulsed pDCs.  Spleens were excised from the mice systemically 
challenged with C. albicans following adoptive transfer with pulsed pDCs.  Yeast 
and hyphal forms of C. albicans were used in 1:1 ratio to stimulate the 
splenocytes.  After 2h of incubation, 2.5 µg/ml of amphotericin B was added to 
prevent Candida overgrowth followed by further incubation of 16 h.  Cytokines in 
the culture supernatants were analyzed by ELISA. * P < 0.05 DC alone  vs. 
experiment groups (pulsed with yeast or hyphae). ** P < 0.05 treated (pulsed with 
PGEx/PGE2) vs. untreated DCs (pulsed with yeast or hyphae). 
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 To boost the immune response in vaccinated mice, a second adoptive 
transfer was introduced followed by a systemic challenge.  In mice vaccinated 
with mDCs, yeast-pulsed, but not hyphae-pulsed DCs induced protective 
responses against systemic infection (Figure 10).  While there was a modest 
decrease in kidney CFUs with yeast-pulsed DCs compared to unpulsed DCs, 
exposure to PGE2 or PGE2 in the DC culture abrogated this effect.  Interestingly, 
mice receiving hyphae-pulsed DCs had increased fungal burden, which was 
further exacerbated with prostaglandin treatment  (Figure 8). This indicated that 
along with exposure to PGE2, morphotype specific responses shift the outcome 
of infection as reported previously [115].  Analysis of splenic Th1 and Th2 
cytokines showed that mice receiving prostaglandin treated DCs produced less 
IL-12 compared with untreated DCs (Figure 11).  In addition there was a trend 
towards increased IL-4 and IL-5 production with hyphae-pulsed DCs, which was 
further increased with prostaglandin treatment (Figure 11).  There were no 
significant differences with IFN-γ, TNF-α, IL-10, or TGF-β production (Figure 10 
and data not shown).  Immunohistochemistry analysis showed increases in PMN 
staining in kidneys of groups that were not protected against systemic infection 
(Figure 12a). There was also increased IL-4 and decreased IL-12 production in 
prostaglandin treated or hyphae pulsed groups compared with the mice receiving 
DCs pulsed with yeast (Figure 12b and d). Overall, however, there was 
exacerbated Th17 cytokines in all groups of mice (Figure 12f and g). 
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Figure 10.  Assessment of protection from C. albicans infection following 
double adoptive transfer with mDCs.  Antigen pulsed mDCs were harvested 
after 18h of stimulation. For vaccination, 5x105  cells were injected via the 
intraperitonial route in 6-8 week old C57BL/6 mice on day 0 and day 7.  Mice 
were inoculated 7 d after the second vaccination by tail vein injection with C. 
albicans strain SC5314 (2.5x105 CFU/mouse). After 7 days post-inoculation, the 
mice were sacrificed, the kidneys excised,  homogenized and serial dilution was 
performed to measure fungal burden. For each group, 4 mice were used.  This 
experiment was repeated four times with similar results.   DC = Dendritic cells 
(plasmacytoid); Y = Yeast cells; H = Hyphae. * P < 0.05 DC alone  vs. 
experiment groups (pulsed with yeast or hyphae). ** P < 0.05 treated (pulsed with 
PGEx/PGE2) vs. untreated DCs (pulsed with yeast or hyphae). 
 
 
 
 66
**
**
**
**
*
** **
 
 
Figure 11.   Secretion of cytokines from splenic cultures of mice receiving 
double vaccination with antigen pulsed mDCs.  Spleens were excised from 
the mice systemically challenged with C. albicans following two adoptive 
transfers with pulsed pDCs.  Yeast and hyphal forms of C. albicans were used in 
1:1 ratio to stimulate the splenocytes.  After 2h of incubation, 2.5 µg/ml of 
amphotericin B was added to prevent Candida overgrowth followed by further 
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incubation of 16 h.  Cytokines in the culture supernatants were analyzed by 
ELISA. * P < 0.05 DC alone  vs. experiment groups (pulsed with yeast or 
hyphae). ** P < 0.05 treated (pulsed with PGEx/PGE2) vs. untreated DCs (pulsed 
with yeast or hyphae). 
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Figure 10 
continued.
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A) Gr-1 (PMN marker)
DC + H + E2 DC + H Isotype Ctrl 
DC DC + Y DC + Y + E2 
DC + H + E2 DC + H Isotype Ctrl 
DC DC + Y DC + Y + E2 
B) IL-12
 
 
Figure 12.  Immunohistochemistry analysis kidneys of mice receiving 
double vaccination with antigen pulsed mDCs. Kidneys were excised from 
mice systemically challenged with C. albicans following two adoptive transfers 
with antigen pulsed pDCs. Tissues were fixed in 10% formalin and processed for 
immunohistochemistry.  5µm sections were cut from paraffin-embedded kidney 
tissue blocks.  Antibodies used along with their respective companies purchased 
from and the dilution used are listed in   
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Table 2.  For heat mediated antigen retrieval, sections were treated with for 20 
min with 10mM sodium citrate buffer, 0.05% Tween 20, pH6.0.  Incubation with 
primary antibody was performed overnight at 4°C whereas incubation with the 
biotin conjugated secondary antibody was performed for 30 min at room 
temperature.  To verify staining specificity, negative control slides or appropriate 
isotype controls antibodies and at the same dilution as that of respective primary 
monoclonal antibodies were used.    These isotype controls used were rat IgG, 
IgM, IgG2b and IgG2a.   Samples were analyzed by light microscopy using 
Olympus BX41 microscope and Qcolor3 software tool. 
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Figure 12 Continued 
 
DC DC + Y DC + Y + E2 
DC + H + E2 DC + H Isotype Ctrl 
C) IFN-
DC DC + Y DC + Y + E2 
DC + H + E2 DC + H Isotype Ctrl 
D) IL-4 
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Figure 12 Continued 
 
 
DC DC + Y DC + Y + E2 
DC + H + E2 DC + H Isotype Ctrl 
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Figure 12 Continued 
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 74
 More dramatic results were seen with double adoptive transfers with pDCs 
in terms of protection.  Mice receiving yeast-pulsed pDCs showed a 3 log 
decrease in fungal CFU in the kidneys at d 7 post-infection (Figure 13).  Similar 
to mDCs, addition of PGE2 or PGEx abrogated the ability of yeast-pulsed pDCs 
to induce protection. Hyphae-pulsed pDC exacerbated infection and addition of 
prostaglandins leads to increased fungal burden.  IL-12 levels from restimulated 
splenocytes correlated with fungal burden, with decreased levels observed in 
mice that were not protected (Figure 14).  IL-4 and IL-5 levels were also 
increased in mice vaccinated with hyphae pulsed pDCs.  Interestingly, IL-6 and 
TGF- levels were also increased in non-protected mice.  While these cytokines 
exert both pro- and anti-inflammatory effects, respectively, the combination of the 
two has been shown to induce development of Th17 cells [180].  However, there 
was no detectable IL-17 or IL-23 measured from splenocytes (data not shown). 
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Figure 13. Assessment of protection from C. albicans infection following 
double adoptive transfer with pDCs. Antigen pulsed pDCs were harvested 
after 18h of stimulation. For vaccination, 5x105  cells were injected via the 
intraperitonial route in 6-8 week old C57BL/6 mice on day 0 and day 7.  Mice 
were inoculated 7 d after the second vaccination by tail vein injection with C. 
albicans strain SC5314 (2.5x105 CFU/mouse). After 7 days post-inoculation, the 
mice were sacrificed, the kidneys excised,  homogenized and serial dilution was 
performed to measure fungal burden. For each group, 4 mice were used.  This 
experiment was repeated four times with similar results.   DC = Dendritic cells 
(plasmacytoid); Y = Yeast cells; H = Hyphae. * P < 0.05 DC alone  vs. 
experiment groups (pulsed with yeast or hyphae). ** P < 0.05 treated (pulsed with 
PGEx/PGE2) vs. untreated DCs (pulsed with yeast or hyphae). 
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Figure 14.  Secretion of cytokines from splenic cultures of mice receiving 
double vaccination with antigen pulsed pDCs.  Spleens were excised from 
mice systemically challenged with C. albicans following two adoptive transfers 
with antigen pulsed pDCs.  Yeast and hyphal forms of C. albicans were used in 
1:1 ratio to stimulate the splenocytes.  After 2h of incubation, 2.5 µg/ml of 
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amphotericin B was added to prevent Candida overgrowth followed by further 
incubation of 16 h.  Cytokines in the culture supernatants were analyzed by 
ELISA. * P < 0.05 DC alone  vs. experiment groups (pulsed with yeast or 
hyphae). ** P < 0.05 treated (pulsed with PGEx/PGE2) vs. untreated DCs (pulsed 
with yeast or hyphae). 
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 Overall, protection was associated with increased Th1 and decreased Th2 
cytokines in the spleen with pDCs.  However, the pattern of cytokines didn’t 
completely match CFUs.  We did not find any conclusive results with intracellular 
cytokines staining from the spleen (data not shown).  There are several studies 
that suggest the cytokine responses associated with protection correlate with 
local kidney responses as opposed to splenic responses [181, 182].  These 
studies have depicted drastically increased expression of cytokine genes, various 
innate immune regulation genes and genes correlated with the initiation of the 
adaptive immune response. Therefore, kidney but not spleen cytokines were 
analyzed by immunohistochemistry.  Staining revealed increased PMN levels in 
mice vaccinated with hyphae pulsed DCs, which was even more dramatic in DCs 
that were treated with PGE2 (Figure 15a). This indicates a lack of resolution of 
inflammation.  Similar to splenic responses, IL-12 was most prevalent in mice 
receiving yeast pulsed DCs (Figure 15b).  There was dramatic IFN-γ staining in 
kidneys of mice vaccinated with yeast pulsed DCs, but not in PGE2 treated or 
hyphae pulsed DC groups (Figure 15c).  Th2 cytokines IL-4 and IL-10 staining 
correlated with a lack of protection, with the most staining observed with hyphae 
+ PGE2 pulsed DCs (Figure 15d and e).  We also observed increased IL-6 
production in non-protected groups, which has previously been associated with a 
virulent infection (Figure 15f) [181].  Perhaps the most dramatic staining was 
observed with Th17 cytokines, IL-17 and IL-23. While little to no kidney staining 
was seen in mice vaccinated with yeast-pulsed DC, heavy staining was seen in 
non-protected groups (Figure 15g and h). Overall, these data indicate that yeast 
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pulsed DC induce a Th1 response, while PGE2 or hyphae shifts the response 
towards a Th2 and over-exuberant local Th17 response. 
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A) Gr-1 (PMN marker)
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DC DC + Y DC + Y + E2 
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DC DC + Y DC + Y + E2 
B) IL-12
 
 
Figure 15.  Immunohistochemistry analysis kidneys of mice receiving 
double vaccination with antigen pulsed pDCs. Kidneys were excised from 
mice systemically challenged with C. albicans following two adoptive transfers 
with antigen pulsed pDCs. Tissues were fixed in 10% formalin and processed for 
immunohistochemistry.  Staining was visualized by light microscopy.   
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Figure 15  Continued 
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Figure 15  Continued  
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Figure 15  Continued  
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Figure 16.  Model for immunomodulation by Candida and PGE2 in (A) 
Spleen and  (B) Kidney. 
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DISCUSSION 
 
 The early cytokine analysis with JAWSII cells revealed upregulation of Th2 
cytokines IL-4, IL-10, and IL-13 in the presence of hyphae with PGE2.  This is 
consistent with the previous data reporting a bias towards non-protective Th2 
cytokine responses in macrophages and monocytes in the presence of hyphae, 
but not yeast [80].  However, the presence of PGE2 was required for robust Th2 
cytokine production from DCs as was reported previously [183].  In addition, pro-
inflammatory cytokines IL-6 and IL-15 were upregulated in the hyphae/PGE2 
group. Although pro-inflammatory mediators are required for clearance of 
Candida, this early inflammatory response also correlates with early expression 
of SOCS-3, a suppressive cytokine, which is involved in promoting a Th2 (DC2) 
phenotype [184].  We did not see any distinct dichotomy of Th1 versus Th2 
response in the yeast versus hyphae treated group perhaps because of the early 
time point (2h).   We also confirmed upregulation of IL-4, IL-6, and IL-10, and 
down-regulation of IL-12 using qRT-PCR.  With this analysis, there were more 
obvious differences between the yeast and hyphae pulsed DCs, with greatest 
responses observed with hyphae pulsed DCs treated with PGE2.  Overall, this 
indicates that PGE2 promotes a non-protective Th2 type response from DCs 
(Figure 16). 
In analyzing the effects of prostaglandins and antigenic stimulation on DC 
maturation and activation, we compared cell surface marker expression in 
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primary bone marrow derived mDCs and pDCs. Overall, the greatest increases in 
CD86 expression occurred in DCs pulsed with hyphae in the presence of PGE2.  
This indicates that DC activation is influence by both C. albicans morphotype and 
PGE2.  Interestingly, there was a more dramatic increase in CD86 with yeast 
pulsed pDCs (3 fold) compared with mDCs (equivalent to control).  This could be 
one reason why we observed increased protection with yeast pulsed pDC 
compared to mDCs during systemic Candida infection after DC vaccination.  This 
pattern is also reported in other studies where PGE2 were responsible for 
upregulation of activation marker in the dendritic cells but in conjunction with a 
cocktail of other compounds [185].  Analysis of early cytokine production by qRT-
PCR confirmed that both mDCs and pDCs behave similarly to the JAWSII cell 
line.  We observed increased IL-4, IL-6 and decreased IL-12 in hyphae pulsed 
DCs in the presence of PGE2.  This confirms the utility of this cell line and 
strengthens the argument that hyphae and PGE2 promote pro-Th2 responses in 
DCs. 
To examine effects of antigenic stimulation and prostaglandins on 
subsequent responses in pDCs and mDCs, we analyzed cytokine production by 
ELISA.  We observed decreased Th1 cytokine production (IL-12 and IL-6) and 
slightly increased Th2 cytokine production (IL-4) in the presence of fungal or host 
PGE2. Studies have shown PGE2 to downregulate Th1 and increase Th2 
responses, which is supportive of the results from our in vitro cytokine analysis 
[183, 186, 187].  However, we also observed decreased IL-10 (Th2 and Treg), 
and IL-23 (Th17). In addition, we did not observe any distinct dichotomy of Th1 
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versus Th2 response in the yeast versus hyphae treated groups.  However, 
PGE2 production was significantly increased in the hyphal pulsed DCs compares 
with yeast pulsed.  Because C. albicans was killed at the 2 h point, this PGE2 
must be host-derived.  Previous studies have shown induction of PGE2 synthesis 
via activation of COX-2 transcription by C. albicans from various immune cells 
like splenocytes, macrophages, and endothelial cells [161, 188, 189].   In 
addition, there are evidences of PGE2 production from antigen presenting cells 
during recurrent Candida vaginitis [190].  
This difference in the pattern of PGE2 induction could be due to various 
possibilities like differential PRR signaling or β-glucan contamination or perhaps 
due to the differences in the concentration of manufacturer’s versus PGEx 
generated in the lab.  DCs recognize yeast and hyphal form of C. albicans via 
TL4 and TLR2 receptors [80, 115, 116].  Also, studies have indicated that C. 
albicans signaling via TLR2 pathway leads to the production of PGE2 from the 
host and causes persistent type of infection [189].  This discrimination by the 
DCs to interact via different TLRs could result from the fact that the hyphal cell 
wall proteins are different from that of the yeast form of C. albicans.  The 
presence of important adhesions like Als3 (Agglutinin like sequence) and Hwp1 
(Hyphal wall protein), which are antigenic and play role in virulence caused by 
this fungus has been associated with hyphal forms [191-193].  Prostaglandins 
produced by both host and fungal cells also enhance morphogenesis in C. 
albicans suggesting that eicosanoids could participate in modulating the immune 
responses by both influencing Candida and DC biology in vivo [156, 162].  Thus, 
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depending on the morphotypes of Candida (yeast or hyphal form), the DCs have 
the ability to modulate the immune responses.  Another factor contributing to the 
differences in the cytokine responses induced from the bone marrow derived 
dendritic cells after stimulation with  PGE2    versus  PGEx  could be because of 
the β-glucan contamination which is one of the main constituent of Candida cell-
wall  polysaccharides [194].  Various studies have reported that β-glucan plays 
active key role towards generating the immune responses by activating the 
complement proteins and inducing array of inflammatory cytokines like TNF-α 
and also leukotrienes from the host cells [195].  There is a possibility that PGEx 
eluted from the anti-PGE2 column got this β-glucan contamination during washing 
the anti-PGE2 column with buffers.  Also, there could be differences in the PGE2 
concentration from the manufacturer’s PGE2 with that of the PGEx which was 
eluted from the anti- PGE2 column for which the concentration was determined 
using the monoclonal ELISA kit.   All these factors might have possibily 
contributed to the differences in the cytokine induction pattern after using these 
compounds for dendritic cell stimulation assay. 
To determine the downstream effects of antigenic stimulation in the 
presence of PGE2, mice were vaccinated with DCs and challenged systemically. 
After one round of vaccination, we observed protection only with pDCs pulsed 
with yeast.  This is in agreement with previous work by Zelante et al., which 
showed that pDCs pulsed with yeast are able to generate protection compared to 
mDCs [79].  However, after two rounds of vaccination, both yeast pulsed pDCs 
and mDCs imparted protection compared to the hyphae pulsed group. This 
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pattern of protective versus non-protective dichotomy with hyphae versus yeast 
pulsed DCs has been documented in previous studies [80]. This could be due to 
the fact that the hyphal but not yeast form of C. albicans was able to induce high 
levels of PGE2 production from the DCs prior to adoptive transfer.   
 An important characteristic of prostaglandin activity is their potency at very 
low (nanomolar) concentrations.  In relation to this potency, most eicosanoids 
have very short half-lives, being made de novo (as opposed to stored and 
released) and acting near the site of their synthesis [134].  Addition of nanomolar 
quantities of PGE2 to yeast-pulsed pDCs or mDCs abrogated their ability to 
induce protection against systemic infection.  The concentration of the PGE2 that 
was used in our experiment were similar to that detected by the DCs at 18h time 
point.   To analyze the type of immune response generated after vaccination, we 
measured re-stimulated splenocyte culture cytokine levels.  With both pDCs and 
mDCs, there was decreased IL-12 and increased IL-5 in groups that were not 
protected after vaccination.  This indicates that protection correlates with 
elaboration of a Th1 response. We also observed increases in IL-4 in mice 
receiving hyphae pulsed DCs, which was further increased with prostaglandin 
exposure. Interestingly, we also observed increased IL-6 and TGF- in non-
protected groups.   These cytokines are sufficient for the induction of IL-17 and 
IL-17F expression in TCR-activated naïve CD4+ T cells [196]. 
The Th17 response also possibly plays a role in generating non-protective 
response, however, this was more pronounced in the mice kidneys than spleen.  
Our studies did not depict any recovery of fungal burden from other organs like 
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mice liver, kidney or blood (data not shown). The findings from the 
immunohistochemistry studies are also in alignment with the pattern of protection 
observed in the mice after adoptive transfer.  The kidneys from yeast pulsed 
mice showed the production of protective Th1 cytokines (IFN-γ and IL-12) 
compared to the other groups, which had more Th2 (IL-4) and pro-inflammatory 
cytokine (IL-6) expression. The most dramatic staining was seen with Th17 
cytokines (IL-17, IL-23) were very strong in the most of the groups except the 
yeast pulsed pDCs indicating that Th17 pathway is associated with non-
protective responses and persistent fungal infection. Although we observed slight 
protection with double adoptive transfer with mDCs pulsed with yeast, there was 
dramatic Th17 cytokine staining in the kidneys.  It could be that there is a 
threshold level of C. albicans fungal burden that initiates this dramatic response.  
With pDCs, C. albicans was held to 102- 103 CFU/g tissue, while with mDCs, 
levels reached 104.   
Other work on C. albicans infections in the GI model have indicated that 
both IL-23 and Th17 are induced in vaccinated mice and are non-protective, 
resulting in defective fungal clearance by impairing the anti-fungal activities of 
PMNs and prolonged inflammation [79]. However, in oral and systemic infection 
models, IL-17 receptor A (IL-17RA) knockout mice are more susceptible to 
infection in naïve animals, indicating that the Th17 pathway is necessary during 
acute infections [108, 123]. Our studies indicate that in later stages of infection in 
vaccinated mice, the Th17 response cytokines is associated with exacerbated 
uncontrolled inflammation.  Both IL-23 and IL-17 can inhibit neutrophil antifungal 
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activity resulting in pathological form of inflammation associated with impaired 
antifungal resistance [79].  Therefore, although neutrophils were recruited to the 
kidneys, the antifungal activity is likely diminished, as indicated by the high fungal 
burden. One of the mechanisms by which this could be verified in future studies 
is by targeting the IL-17 pathway at different points of infection (early, 
intermediate and late) with antibody-mediated IL-17 depletion in naïve vs. 
immunized animals.   Ours is the first study to report presence of Th17 cytokines 
in the mice kidneys during systemic candidiasis is associated with a lack of 
protection. 
 Our studies using DC vaccination allowed us to investigate downstream 
effects of host and fungal prostaglandins on Candida-DC interactions.  Our 
results indicate that the presence fungal PGE2 (PGEx) or PGE2 during the host-
pathogen interaction with DCs can drive a non-protective response. This is 
associated with generation of a non-protective Th2 response and repression of a 
protective Th1 response.  Locally, we also observed exacerbated Th17 
responses and uncontrolled fungal growth despite the presence of neutrophils at 
the site of infection (Figure 16).  This study indicates that local host or fungal 
PGE2 production could shift responses in favor of the fungus, which is 
detrimental during systemic infection. Therefore, fungal PGE2 production may be 
considered a virulence factor.  Understanding the interactions between PGE2 and 
its effect on DCs is important towards developing potent therapeutic strategies to 
treat Candida infection.  This is especially important given the fact that Candida 
infections are associated with high mortality rate and the antifungal agents like 
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fluconazole, voriconazole, itraconazole etc. are associated with resistance 
mechanisms [197-199].  In future, this study will also help towards understanding 
the prostaglandin pathways and its downstream effects that can be extended 
towards other pathogenic eukaryotic species.  
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CHAPTER 2 
Effect of PGEx and PGE2 on C. albicans uptake and 
survival in macrophages 
ABSTRACT 
 
 Macrophages play key roles in protecting against both mucosal and 
systemic infections with the opportunistic fungal pathogen Candida albicans.  
However, mechanisms controlling antifungal killing defenses of these phagocytes 
are not well understood.  C. albicans produces an immunomodulatory oxylipin 
called PGEx, that is structurally and functionally similar to host PGE2.  In addition, 
it can produce authentic PGE2 from host arachidonic acid.  To determine the 
effects of fungal and host prostaglandins on interactions with macrophages, we 
studied phagocytosis and intracellular survival, as well as production of reactive 
oxygen and nitrogen species.  Addition of PGE2 or PGEx inhibited phagocytosis, 
while promoting intracellular survival of C. albicans in RAW264.7 cells.  However, 
increased survival was not accompanied by any reduction in nitric oxide or 
peroxynitrite.  Therefore, the effects of these compounds may involve non-
oxidative mechanisms that require further investigation. 
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INTRODUCTION 
 
C. albicans is an opportunistic fungal pathogen that inhabits mucosal 
surfaces including the oral cavity, gastrointestinal tract, and vagina [200].  Under 
conditions that permit the outgrowth of Candida, mucosal colonization can lead to 
infection and dissemination. Diseases range from superficial mucosal infections 
to life-threatening systemic candidiasis. Risk factors for systemic infection include 
immunocompromise, antibiotic therapy, and the use of indwelling medical 
devices.  Protective immune responses to candidal infection require both innate 
and adaptive immunity. There is no evidence of complement or antibody 
mediated clearance of C. albicans infection.  Therefore, the first line of defense 
against infection involves activated innate effector cells, including neutrophils and 
macrophages.   
Macrophages play an essential role during systemic candidiasis. During C. 
albicans systemic infection, mice depleted of macrophages exhibit delayed 
clearance and high kidney fungal burden [201]. Macrophages have direct 
antimicrobial activity against such organisms and also promote antigen 
presentation, polysaccharide sequestration, and production of cytokines and 
chemokines. Mechanisms implemented by macrophages to combat infection 
must involve killing C. albicans, both yeast and hyphal form. If C. albicans 
survives intracellularly, macrophages could act as a vehicle to disseminate the 
fungus to immunological privileged niches, which could result in escape from 
innate and adaptive immune responses generated by the host [202]. There is 
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also evidence that persistent infection is associated with the intracellular 
residence of yeast cells in macrophages.   
Macrophages can kill Candida via oxygen-dependent or independent 
pathway [203]. Oxygen dependent pathways include production of both reactive 
oxygen and nitrogen intermediates (ROI, RNI).  In particular, nitric oxide (NO) 
has strong antifungal activity; however, C. albicans can evade host defense by 
suppression of NO/superoxide radical production by stimulated macrophages 
[103-105]. Furthermore, what were thought to be two independent pathways, i.e., 
nitric oxide and superoxide anion, have now been shown to combine to form a 
potent macrophage candidacidal molecule, peroxynitrite. Oxygen independent 
pathways are less well studied.  However, upon phagocytosis of C. albicans, 
yeast forms can germinate and lyse macrophages [106].  Therefore, whether the 
macrophage or the fungus prevails is dependent on several factors, including the 
type of macrophage and activation state.  
Activation of macrophages is influenced by the microenvironment as well 
as the nature of the microbe or antigen.  Whereas Th1 cytokines such as IFN 
and TNF- stimulate antifungal activities, Th2 cytokines such as IL-10 are 
inhibitory [204, 205].  C. albicans has also been shown to produce eicosanoids, 
which are potent immune response regulators derived from arachidonic acid 
(AA).  C. albicans produces a compound that cross-reacts with antibodies to host 
prostaglandin E2 (PGE2), called PGEx.  In the presence of host AA, PGEx 
production is significantly upregulated, indicating that C. albicans can produce 
PGE2 from host lipid precursors.  Mass spectrometry analysis revealed that 
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PGEx derived from AA is structurally identical to PGE2 [154]. Overall, 99.9% of 
AA-derived PGEx is PGE2.  In terms of macrophages, PGE2 can inhibit 
phagocytosis and intracellular killing of bacteria [206, 207].  However, other 
reports have indicated that PGE2 is crucial for phagocyte killing of parasites, via 
induction of nitric oxide [208].  In the present study, we tested the effect of fungal 
PGE2 (PGEx) and host PGE2 on Candida phagocytosis and survival in 
macrophage cell line, RAW264.7 and how these compounds influence oxidative 
killing mechanisms. 
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MATERIALS AND METHODS 
 
 
Cell culture.  The macrophage cell line RAW264.7 (originally from ATCC TIB 
67) was kind gift from Dr. M.  Neely (Wayne State University, Detroit, MI).  Cells 
were cultured in Dulbecco’s modified eagle’s medium (DMEM) supplemented 
with 10% heat inactivated fetal bovine serum, 25mM HEPES, 2 mM Glutamine, 
100 IU penicillin/ml and 100µg streptomycin/ml (D-10 medium) and incubated at 
37°C, 5% CO2 with 95% humidity.  For experiments, cells were seeded in 
100 cm2 T75 flask at the density of 1.5 X105 cells /ml. 
 
C. albicans Strains and Culture Conditions.  The C. albicans strain SC5314 
used in this study is a prototrophic parental strain [168]. This strain was 
subcultured from frozen stocks and grown overnight at 30°C in Sabouraud 
dextrose agar (SDA) (Becton, Dickinson and Company, Sparks, MD).  For the 
liquid cultures, isolated colonies from the SDA plates were inoculated into 
Sabouraud dextrose broth (SDB) with constant shaking.   
 
Isolation of fungal PGEx.  C. albicans strain SC5314 was grown overnight at 
37C in 10 ml RPMI containing 100 mM arachidonic acid.  Culture supernatants 
were loaded onto a PGE2 affinity column (Caymen Chemical), washed, and 
eluted according to manufacturers instructions.  The eluates were dried under a 
stream of nitrogen gas and resuspended in 500 µl PBS. PGEx concentrations 
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(approximately 20ng) determined using a PGE2 monoclonal ELISA (Cayman 
Chemical, Ann Arbor).  
 
Phagocytosis assay.  Overnight C. albicans cultures were washed 2-3 times 
with 10% DMEM at 4°C by centrifuging at 4000 xg.  Sonication was performed at 
the highest setting for 10 min followed by keeping it on the ice for 30 min to 
obtain single cell suspensions.  Macrophages were infected with C. albicans at 
an MOI of 5 in the presence or absence of PGE2 or PGEx at a final concentration 
of 2nM.  After 15min or 3h of incubation, the supernatant was removed and the 
cells were washed three times with 1ml sterile 1x PBS to remove non-adherent 
organisms.  To obtain phagocytosed yeast, macrophages were lysed with sterile 
water.  The recovered yeast cells, from the supernatant fraction as well as after 
lysis, were plated on SDA media after serial dilution.  The formula used for 
calculations: 
% phagocytosis = 1 – [CFU t(initial)/intracellular CFU t(15 min)] X 100 
% Intracellular killing = 1 – [intracellular CFU t(15 min)/intracellular CFU t(3 h)] X 
100 
 
Fluorescence microscopy.  For monitoring phagocytosis in macrophages, 
RAW264.7 cells seeded on coverslips at a concentration of 106 cells/ml. C. 
albicans was stained with 1µl calcufluor at a concentration of 1mg/ml (Fluka, 
Seelze, Germany) for 10 min at 1x106 yeast cells per 200 µl and added to 
macrophages at an MOI of 5.  To monitor phagocytosis after 15 min incubation, 
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the supernatant was washed and staining of extracellular non-phagocytosed 
yeast was quenched with trypan blue.  Cells were fixed with 4% 
paraformaldehyde (in PBS) at 4°C for 10min.  To monitor intracellular survival at 
3 h, cells were incubated as previously mentioned but Candida was pre-stained 
with FUN-1 fungal viability stain according the manufacturer’s instructions 
(Invitrogen).  FUN-1 distinguishes live (red) versus dead (green/yellow) yeast.  
For fluorescence microscopy, a Nikon Eclipse E800 and Metamorph software 
was used. 
 
Growth curve.  C. albicans was grown overnight in SD broth while shaking at 
30C.  The culture was washed, counted, and diluted into 10 ml fresh SD broth at 
a final concentration of 105/ml.  PGEx or PGE2 was added to a final concentration 
of 2nM and culture were incubated at 30°C with shaking.  The absorbance was 
measured at 600nm at various time points up to 48h.  For the blank (control) 
sample, only SDB without yeast was used.  CFU analysis was performed by 
serial dilution of the cultures at various time points and plating onto SD agar 
plates. 
 
Nitrite Assay. RAW264.7 cells were plated at a concentration of 5x105 cells/ml 
in 24-well plates and grown for 24 h with or without L-NMMA (competitive NOS 
inhibitor) at final concentration of 500µM 24 h prior to infection. Cells were 
stimulated with LPS (1µg/ml final concentration) and infected with C. albicans at 
MOI 10:1. Cells were incubated at 37°C, 5% CO2 for 3h.  Both PGEx and PGE2 
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were used at a final concentration of 2nM. The 24-well plate was centrifuged at 
1000 rpm for 10 min and nitrite levels in cell supernatants were assayed using a 
Griess reagent kit (Molecular Probes) according to the manufacturer’s 
instructions.  
 
Peroxynitrite Assay.  RAW264.7 cells were plated at a concentration of 5x105 
cells/ml in 24-well plates and grown for 24 h.  Cells were washed and stimulated 
with LPS (1µg/ml final concentration) and infected with C. albicans at MOI 10:1 
for 3h. Both PGEx and PGE2 were used at a final concentration of 2nM. Control 
cells were stimulated with zymosan (200µg/ml final concentration). Cells were 
incubated at 37°C, 5% CO2 for 3h.  The plate was centrifuged 1000 rpm for 10 
min and peroxynitrite levels in cell supernatants were assayed using a 
peroxynitrite detection kit (Cell Technology Inc.) according to the manufacturer’s 
instructions.   
 
Statistical analysis.  The Student’s t test (two-tailed, unequal variance) was 
used to analyze the significance of differences between two experimental groups.  
Significance was considered with a P < 0.05 or less.  The data recorded are 
representative of either two or three independent experiments.  
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RESULTS 
 
To study the effect of prostaglandin (PGEx and PGE2) on macrophage 
phagocytosis of C. albicans, viable intracellular yeast were monitored 15 min 
after infection.  The data showed a decrease in percentage of phagocytosis in 
the prostaglandin treated groups.  Phagocytosis decreased by about 20% in the 
PGEx treated group, whereas in the PGE2 treated group, percent phagocytosis 
was reduced by about 10% (Figure 17). 
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Figure 17.  Effect of PGE2 and PGEx on macrophage phagocytosis of C. 
albicans. C. albicans strain SC5314 was grown overnight in SD broth at 30°C.  
Cultures were washed with D-10 medium followed by sonication to create a 
single cell suspension. RAW264.7 cells were infected at an MOI of 5 in the 
presence or absence of PGE2 or PGEx at a final concentration of 2nM.  After 15 
min, supernatant was removed and cells were washed three times with sterile 1X 
PBS.  Cells were lysed with sterile water and both supernatants and lysates were 
diluted and plated onto SD plates to determine CFU.  The experiment was 
repeated 4 times in triplicate.   
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 To determine if prostaglandins influence subsequent intracellular survival 
viable yeast were monitored 3 h post-infection.  We observed a modest increase 
in intracellular survival in the macrophages treated with PGE2 (Figure 18).  
However, there was a significant increase in intracellular survival with 
macrophages treated with PGEx compared to the control group (Figure 18). To 
further verify the increase in phagocytosis, we performed fluorescence 
microscopy.  C. albicans was labeled with calcofluor white and used to infect 
macrophages seeded onto cover slips.  We observed an increase in the number 
of intracellular yeast in the presence of PGE2 or PGEx compared to the control 
group (Figure 19).  Staining of C. albicans with FUN-1 also showed increased 
viable yeast in prostaglandin treated macrophages, particularly with PGEx 
(Figure 20).  To rule out the possibility that prostaglandin was directly contributing 
to the growth or budding of C. albicans, we performed growth curve assays.  C. 
albicans was incubated in the presence of PGE2 or PGEx and growth was 
monitored over 48 h. We observed no increases in presence of prostaglandin at 
early or late time points (Figure 21). 
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Figure 18. Effect of PGE2 and PGEx on intracellular survival of C. albicans 
in macrophages. C. albicans strain SC5314 was grown overnight in SD broth at 
30°C.  Cultures were washed with D-10 medium followed by sonication to create 
a single cell suspension. RAW264.7 cells were infected at an MOI of 5 in the 
presence or absence of PGE2 or PGEx at a final concentration of 2nM. PGEx 
was obtained by passing the overnight cultured Candia supernatant 
supplemented with 100mM arachidonic acid through anti-PGE2 column.  PGE2 
was commercial standard prostaglandin obtained from Cayman chemicals, Ann 
Arbor.  After 15 min, supernatant was removed and cells were washed three 
times with sterile 1X PBS.  Cells were lysed with sterile water and both 
supernatants and lysates were diluted and plated onto SD plates to determine 
CFU.  The experiment was repeated 4 times in triplicate. Experiments were 
repeated 3 times with 3 replicates each. * P < 0.05 control vs. experiment group. 
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Figure 19.  Effect of PGE2 and PGEx on C. albicans phagoctysosis by 
immunofluorescence microscopy. C. albicans strain SC5314 was grown 
overnight in SD broth at 30°C.  Cultures were washed with D-10 medium 
followed by sonication to create a single cell suspension. Yeast were stained with 
calcofluor white prior to infection. RAW264.7 cells were seeded onto cover slips 
and infected  at an MOI of 5 in the presence or absence of PGE2 or PGEx at a 
final concentration of 2nM. After 3h incubation, the supernatant was washed and 
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quenched with  trypan blue to destain the non-phagocytosed yeast.  Cells were 
fixed with 4% paraformaldehyde and analyzed by fluorescence microscopy using 
a  Nikon Eclipse E800 with Metamorph software.  Data is representative of three 
independent repeats. 
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Figure 20.  Effect of PGE2 and PGEx on C. albicans intracellular viability. C. 
albicans strain SC5314 was grown overnight in SD broth at 30°C.  Cultures were 
washed with D-10 medium followed by sonication to create a single cell 
suspension. Yeast were stained with FUN1 prior to infection, which distinguishes 
live (red) from dead (green-yellow) fungi. RAW264.7 cells were seeded onto 
cover slips and infected  at an MOI of 5 in the presence or absence of PGE2 or 
PGEx at a final concentration of 2nM.  After 3 h incubation, the cells were 
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washed and analyzed by fluorescence microscopy using a  Nikon Eclipse E800 
with Metamorph software. Data is representative of three independent repeats. 
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Figure 21.  Effect of PGE2 and PGEx on C. albicans growth in vitro. C. 
albicans was grown overnight in SD broth while shaking at 30C.  The culture 
was washed, counted, and diluted into 10 ml fresh SD broth at a final 
concentration of 105/ml.  PGEx was obtained by passing the overnight cultured 
Candia supernatant supplemented with 100mM arachidonic acid through anti- 
PGE2 column.  PGE2 was obtained as commercial standard prostaglandin from 
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Cayman chemicals, Ann Arbor. PGE2 and PGEx was added to a final 
concentration of 2nM and culture were incubated at 30°C with shaking. A) The 
absorbance was measured at 600nm at various time points up to 48h.  For the 
blank (control) sample, only SDB without yeast was used.  B) CFU analysis was 
performed by serial dilution of the cultures at various time points and plating onto 
SD agar plates. Data is representative of three indepdendent experiements 
assayed in duplicate. 
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While macrophages possess both oxygen dependent and independent 
antimicrobial defenses, it has been suggested that the oxidative burst is the 
major antifungal defense. This is due to the fact that yeast germinate with 
macrophages, which leads to cell lysis.  Both reactive oxygen and nitrogen 
species (ROI/RNI) production contribute to the candidicidal activity of 
macrophages, with nitric oxide and peroxynitrite exhibiting the strongest 
antifungal activity [205, 209].  We tested the effect of prostaglandins on inhibiting 
nitrite and peroxynitrite during infection with C. albicans.  Macrophages were pre-
treated with or without L-NMMA, a competitive iNOS inhibitor, 24 h prior to 
infection.  The results showed a trend in the decrease of nitrite production in 
each group, which was associated with a slight increase in fungal burden (Figure 
22).  However, in the PGEx treated macrophages, L-NMMA treatment had no 
effect on fungal survival.  This indicates that the effect of PGEx on increasing 
intracellular survival is not due to repression of iNOS and nitric oxide production.  
There were also no significant differences in peroxynitrite production in the 
presence of PGE2 or PGEx (Figure 23). Therefore, prostaglandins must work to 
increase intracellular survival by influencing other antifungal pathways. 
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Figure 22.  Effect of PGE2 and PGEx on NO production by macrophages. 
RAW264.7 cells were seeded overnight in 24-well plate with or without L-NMMA 
(competitive NOS inhibitor) at final concentration of 500µM 24 h prior to infection. 
Cells were stimulated with LPS (1µg/ml final concentration) and infected with C. 
albicans at MOI 10:1 for 3h. Both PGEx and PGE2 were used at a final 
concentration of 2nM. The 24-well plate was centrifuged at 1000 rpm for 10 min 
and nitrite levels in cell supernatants were assayed using a Griess reagent kit 
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(Molecular Probes) according to the manufacturer’s instructions. Data is 
representative of three independent repeats performed in triplicate. * P < 0.05 
control vs. experimental group.  
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Figure 23.  Effect of PGE2 and PGEx on NO production by macrophages. 
AW264.7 cells were plated at a concentration of 5x105 cells/ml in 24-well plates 
and grown for 24 h.  Cells were washed and stimulated with LPS (1µg/ml final 
concentration) and infected with C. albicans at MOI 10:1 for 3h. Both PGEx and 
PGE2 were used at a final concentration of 2nM. Control cells were stimulated 
with zymosan (200µg/ml final concentration). Cells were incubated at 37°C, 5% 
CO2 for 3h.  The plate was centrifuged 1000 rpm for 10 min and peroxynitrite 
levels in cell supernatants were assayed using a peroxynitrite detection kit 
according to the manufacturer’s instructions. Data is representative of three 
independent repeats performed in triplicate.   
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DISCUSSION 
 
 
 Macrophages are potent antifungal effector cells that are required for 
defense against both mucosal and systemic infections with C. albicans [201, 
210].  Macrophages have the ability to kill both yeast and hyphal forms of C. 
albicans.  However, intracellular killing is restricted to the yeast form, as the 
hyphal form is not phagocytosed, presumably due to the large size [211].  
Intracellular killing is particularly important, as survival within the macrophage 
could lead to dissemination using the host cell as a vehicle to evade other 
immune effector responses.  Therefore, interactions that govern intracellular 
survival are of interest in terms of controlling infection.  C. albicans produces a 
PGE2 cross reactive compound called PGEx from endogenous lipid precursors 
that behaves like host PGE2.  Because PGEx works similar to PGE2, it is likely 
that the ring group which is recognized by EP receptors is similar, but the overall 
carbon length in shorter.  In addition, in the presence of arachidonic acid, 
Candida produces copious amounts of authentic PGE2.  Approximately 99.9% of 
the PGEx derived from arachidonic acid is PGE2.  We therefore tested the effects 
of commercially available PGE2 and fungal PGEx (99.9% PGE2) on influencing 
macrophage antifungal activity.   
    Our data shows that PGEx and PGE2 can decrease phagocytosis and 
increase intracellular survival of C. albicans within macrophages.  Interestingly, 
these results were more dramatic with PGEx, compared with PGE2. Firstly, the 
percentage of phagocytosis decreased by about 20% in the PGEx treated 
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groups, whereas in the PGE2 treated group, percent phagocytosis came down by 
about 10% (Figure 1).  Secondly, we observed an increase in the intracellular 
survival of C. albicans inside the macrophages by about 10% in the PGE2 treated 
group and approximately by 60% in the PGEx treated group compared to the 
control (Figure 2).  This was further verified with our fluorescence microscopy 
data (Figure 3 and Figure 4).  These experiments confirmed that host PGE2 and 
fungal PGEx aid in overcoming antifungal defenses of macrophages.  The fact 
that PGEx produced a more potent response may be due to effects of the 
endogenous PGE2 cross-reactive compound that is co-isolated with fungal PGE2.  
In addition, this may be due to slight variations in the concentration of PGEx.  
Concentrations of PGEx were determined by ELISA, while the commercially 
available PGE2 was determined by analytical methods by the manufacturer. 
The effect of PGE2 and PGEx on increasing intracellular survival did not appear 
to be due to the direct effect of prostaglandins on C. albicans growth.  This is 
based upon our observation from the growth curve study over a period of 48h 
(Figure 5).  There was no change in the density of C. albicans in presence of 
prostaglandins compared to untreated cells.  C. albicans can use arachidonic 
acid as a sole carbon source, which is structurally very similar to PGE2 [212]. 
However, levels of this fatty acid that promote growth are much higher than those 
used in our assays (micromolecular vs. nanomolecular).  Therefore, it is unlikely 
that prostaglandin treatment was used as a nutrient by C. albicans during 
macrophage infection. This data implies that there is perhaps some other 
 
 117
uncharacterized mechanism implemented by prostaglandins that aids in the 
intracellular survival of C. albicans inside RAW264.7 cells. 
 Preliminary advances have been made in our understanding of how C. 
albicans interacts with RAW264.7 cells in presence of prostaglandins, but large 
gaps in our knowledge still remains to verify the underlying mechanism.  
Macrophages employ several candidacidal mechanism to eliminate C. albicans 
[202].  Treatment with PGE2 or PGEx resulted in increased intracellular survival, 
which may be due to effects on one specific or combination of various 
candidacidal mechanisms such as suppression of reactive oxygen, nitrogen 
intermediates, alteration of trafficking or pH. Previous studies have depicted that 
hyphal form but not yeast form are susceptible to extracellular antifungal 
mechanisms employed by macrophages, which likely involves reactive oxidative 
products [211].  Therefore, it is assumed that the yeast form must be eliminated 
by phagocytosis and intracellular killing methods.   
Both reactive oxygen and nitrogen species (ROI/RNI) production 
contribute to the candidicidal activity of macrophages, with nitric oxide and 
peroxynitrite exhibiting the strongest antifungal activity [205, 209]. In addition, a 
complex “cross-regulation” takes place between the COX and NO pathways. It 
has been reported that PGE2 can either activate or inhibit NO production 
depending on the microenvironment NO [213, 214], in part derived from iNOS, 
negatively regulates the immediate-early induction of COX-2 in response to 
inflammatory stimuli [215].  Therefore, we examined the effect of host and fungal 
prostaglandins on RNI production by macrophages. Our data indicate that a nitric 
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oxide synthase inhibitor slightly reduced NO production from macrophages, 
which resulted in increased fungal burden in control and PGE2 treated groups.  
However, with PGEx treated groups, we observed no increase in fungal burden 
in the presence of the inhibitor.  This may be due to the fact that fungal burden 
was already maximal with PGE2 treatment.  However, neither PGE2 nor PGEx 
alone inhibited nitric oxide or peroxynitrite production; therefore, this is not the 
mechanism of action of these compounds.   
Another main antimicrobial mechanism employed by macrophages is 
intracellular killing by phagolysosomal fusion, which results in a reduction in pH 
and activation of degradative enzymes.  It has been reported that phagocytosed 
yeast traffic to late endosomes and fuse with lysosomes [216].  This is followed 
by germination into hyphae, which distends the host cell membranes, resulting in 
escape from the macrophage.  Germination was found to be dependent on the 
reduction in pH associated with phagolysosomal fusion.  Hyphae, which are not 
phagocytosed, can penetrate macrophages and also acquire lysosomal markers 
on the surface of the endosome.  This indicates that internalization and 
phagolysosomal fusion C. albicans favors intracellular survival and potentially 
virulence [216].  Keeping that in mind, it would be worthwhile to study the effects 
of PGEx and PGE2 on changes in phagolysososmal fusion and pH during C. 
albicans infection. 
In summary, our results suggest that host PGE2 and fungal PGEx can 
influence fungal survival during interaction of C. albicans with macrophages.   In 
terms of fungal infection, production of prostaglandin by either the host or the 
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fungus may influence the outcome of the interaction.  However, fungal PGEx is 
more potent than host PGE2 overall.  Intracellularly, this compound may exert a 
more directed response, inhibiting antifungal effector activity within the target cell.  
Therefore, development of drugs that specifically inhibit fungal prostaglandin 
production is warranted.   
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CHAPTER 3  
Role of Eicosanoids in Defense Against Mucosal and 
Systemic Candidiasis 
ABSTRACT 
 
 Candida albicans produces both endogenous prostaglandin-like 
compounds as well as authentic prostaglandins (PGE2) from host arachidonic 
acid.  Prostaglandin production is highest in the hyphal or biofilm form of C. 
albicans, which are both associated with increased virulence or ability to cause 
infection. Synthesis of fungal prostaglandins can be inhibited in vitro with 
eicosanoid inhibitors.  In addition, these inhibitors can interfere with C. albicans 
germination and biofilm formation.  Therefore, we tested whether eicosanoid 
inhibitors can affect the outcome of either mucosal infection (vaginitis) or 
systemic infection (intravenous route) in mice. We compared the effects of a 
traditional antifungal drug, amphotericin B, with two eicosanoid inhibitors that had 
been previously shown to inhibit C. albicans eicosanoid production in vitro 
(NDGA and indomethacin).  NDGA is a plant polyphenol and inhibits both COX 
and lipoxygenase (LO), while indomethacin is a non-selective COX inhibitor.  In 
both types of infections, NDGA treatment resulted in decreased fungal burden.  
This correlated with decreased PGE2 levels in the host, as well as alterations in 
cytokine expression.  Therefore, eicosanoid inhibitors may useful in combination 
with conventional antifungal agents in treating fungal infections.   
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INTRODUCTION 
 
Mucosal and systemic infections caused by C. albicans pose a significant 
clinical threat to the immunocompromised and immunocompetent population [2, 
3].   Various persistent forms of infections such as recurrent vaginitis, are 
associated with increased C. albicans colonization and are associated with 
increased PGE2 levels locally [217]. Previous studies have demonstrated the 
production of PGE2 from both C. albicans and host cells, although, the 
understanding of their role towards pathogenesis and persistence is still at 
nascent stage.  Thus prostaglandins might have some key role to play towards 
promoting fungal virulence. Therefore, it is important to study the effect of this 
compound in C. albicans colonization, infection, and modulation of immunity. 
 Prostaglandins are pleiotropic molecules that regulate a variety of 
physiological processes including modulation of immune response [218].  They 
can elicit both pro- and anti-inflammatory responses.  In terms of innate 
immunity, PGE2 can inhibit macrophage phagocytosis and activation and 
influence dendritic cell maturation and cytokine production.  In terms of adaptive 
immunity, PGE2 has also shown to be able to inhibit Th1 type of adaptive 
immune response and promote Th2 type of responses, the later being associated 
with non-protective immune response to C. albicans infection [219-222].  
Prostaglandins can be produced by both Candida and the host cells [156, 160, 
223].  In mammalian cells, prostaglandins are produced from the arachidonic 
acid precursor by the action of cyclooxygenase (COX) enzymes, both COX-1 and 
COX-2.  COX-1 is constitutively expressed for steady state production of 
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eicosanoids, whereas COX-2 is an inducible form associated with immune 
responses [224].  Previous in vitro studies have demonstrated that C. albicans 
induces PGE2 production from host cells via the COX-2 pathway [161].  
Precursors of C. albicans oxylipins can also be used by COX-2 to produce array 
of other lipid compounds.  This emphasizes the presence of transcellular 
host/fungal eicosanoid pathway [225].   Studies by Douglas et al. have depicted 
that nonsteroidal anti-inflammatory drugs (NSAIDS), which are cyclooxygenase 
inhibitors, had inhibitory effects on C. albicans germination and biofilm formation, 
activities associated with infection and virulence [226].  These drugs have the 
capacity to inhibit the prostaglandin formation from host cells by inhibiting the 
action of the enzyme(s) COX-1 or COX-2 or both [224].  To this end, in this study 
we examined the role of host eicosanoids in both mucosal (vaginitis) and 
systemic infection models through administration of prostaglandin inhibitors. 
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MATERIALS AND METHODS 
 
Mice.  Female retired breeders or 6-8 week old mice of C57BL/6 strain were 
obtained from Charles River Laboratories (Wilmington, MA). All mice were 
maintained at an American Association for the Accreditation of Laboratory Animal 
Care-accredited animal facility at Wayne State University (WSU) and housed in a 
pathogen-free environment in accordance with the procedures outlined in the 
Guide for the Care and Use of Laboratory Animals under an animal study 
proposal approved by the WSU animal investigation committee. 
 
C. albicans Strains and Culture Conditions.  The C. albicans strain SC5314 
used in this study is a prototrophic parental strain [168]. This strain was 
subcultured from frozen stocks and grown overnight at 30°C in Sabouraud 
dextrose agar (SDA) (Becton, Dickinson and Company, Sparks, MD). For liquid 
cultures, isolated colonies from the SDA plates were cultured in Sabouraud 
dextrose broth (SDB) with constant shaking.  To obtain hyphal form, yeast form 
of C. albicans was added to RPMI supplemented with 10% FBS at the 
concentration of 1 x 106 Candida per ml of media.  Hyphae were generated after 
2 h incubation at 37°C. 
 
Vaginal infection model. Three days prior to inoculation, mice were 
subcutaneously injected with 0.01 mg/mouse of 17estradiol valerate (Sigma) 
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dissolved in sesame oil.  This was followed with estrogen administration at every 
one week interval [43].  The control groups of mice received estrogen treatment 
and were mock inoculated with PBS.  On day 0, mice were inoculated 
intravaginally with 5x106 C. albicans in 30µl PBS using a pipette.  On day 2, mice 
were administered amphotericin B or eicosanoid inhibitors (NDGA, 
indoemethacin) vaginally at the concentration of 25 mg/kg.  After 6 days of drug 
administration, the mice were euthanized on day 7 and the CFU were recovered 
after lavaging vaginal tissues twice with sterile PBS (each wash 50µl).  The 
vaginal fungal burden was analyzed by performing serial dilutions of vaginal 
lavage samples and plating them on SDA plates.   
 
Vaginal Homogenates.  For cytokine analysis in the vaginitis model, vaginal 
tissue was excised and homogenized in 1ml of buffer containing PBS, 0.05% 
Triton X-100, and protease inhibitor.   This volume was further centrifuged at 
800g for 5 min to remove the cellular debris and the clear supernatant was 
collected for cytokine analysis. Previous studies have demonstrated that 
presence or absence of homogenized tissue does not interfere with the levels of 
endogenous cytokines following the homogenization process [43]. 
 
Systemic infection model. Mice were challenged by intravenous tail injection 
with C. albicans at the concentration of 2.5 X 105 CFU/mouse in 250 µl of sterile 
PBS using a 30-gauge needle attached to a 1-ml syringe. The mice challenged 
with C. albicans were treated with amphotericin B (amphotericin B) or eicosanoid 
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inhibitors (nordihydroguaretic acid/NDGA), indomethacin) at different 
concentrations (5, 10, 25 mg/kg) subcutaneously daily for 6 post-infection.  On 
day 7, the kidneys were harvested for CFU analysis and the spleens for cytokine 
analysis.  
 
CFU Assay.  To determine the amount of fungal growth in the organs of the 
mice, the kidney and the liver were weighed and homogenized using a tissue 
tearor.   Serial dilutions of tissue homogenates were made in sterile water and 
were plated onto SD agar to determine the CFU per gram per organ in each 
group of mice. 
 
Splenocyte cultures.  For the analysis of cytokines induces in the systemic 
model, spleens were excised from the C. albicans infected mice and the 
splenocytes were isolated from them.  A 1:1 ratio of both yeast and hyphal forms 
of C. albicans were used at MOI 1:2 to stimulate the splenocytes.  After 2 h of 
incubation, 2.5 µg/ml of amphotericin B was added to prevent Candida 
overgrowth followed by further incubation of 16 h at 37°C, 5% CO2 incubator.  
The supernatants were collected and the levels of cytokines were measured by 
ELISA.  
 
Splenocyte Harvest and Pulsing.  Spleens were excised from the C. albicans 
infected mice and the splenocytes were isolated from them.  A 1:1 ratio of  both 
yeast and hyphal forms of C. albicans were used at MOI 1:2 to stimulate the 
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splenocytes.  After 2 h of incubation, 2.5 µg/ml of amphotericin B was added to 
prevent Candida overgrowth followed by further incubation of 16 h at 37°C, 5% 
CO2 incubator.  The supernatants were collected and the levels of cytokines 
were measured by ELISA. 
 
Enzyme Linked Immunosorbent Assay.  Cell culture supernatants (DCs and 
splenocyotes) were analyzed for the following cytokines by ELISA:  IL-4, IL-5, IL-
6, IL-10, IL-12, IL-13, IFN-γ, TGF-β, TNF-α, and IL-23.  The detection limits  
(pg/ml) for the assays were <3.90 for IL-4,  < 3.90 for IL-5,  <3.90 for IL-6,  < 
31.25 for IL-10, <15.62 for IL-12, <3.90 for IL-13,  < 15.62 for IFN-γ, <62.5 for 
TGF-β, <7.81 for TNF-α and <7.81 for IL-23 (eBioscience).  In addition, vaginal 
lavages and serum samples were also tested to analyze the levels of PGE2 
(Cayman chemicals). The absorbance of the plates was measured at 450nm 
using Multiskan Ex microplate reader (Thermo Electron Corporation) and 
analyzed with Ascent Software. 
 
Statistical Analysis.  The Student’s t test (two-tailed, unequal variance) was 
used to analyze the significance of differences between two experimental groups.  
Significance was considered with a P < 0.05 or less.  The data recorded are 
representative of either two or three independent experiments. 
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RESULTS 
 
 
 To investigate the effects of eicosanoid inhibitors on the course of 
mucosal candidiasis, we inoculated the estrogenized mice vaginally with C. 
albicans. We compared the effects of a traditional antifungal drug, amphotericin 
B, with two eicosanoid inhibitors that had been previously shown to inhibit C. 
albicans eicosanoid production in vitro (NDGA and indomethacin) [154].  NDGA 
is a plant polyphenol and inhibits both COX and lipoxygenase (LO), while 
indomethacin is a non-selective COX inhibitor. The drugs were administered 
vaginally daily from day 2 to day 7 at a concentration of 25 mg/kg.  This 
concentration was chosen based on previous studies using topical or oral 
administration [227-229].  On day 8, the mice were sacrificed and their vaginal 
fungal burden and induced cytokine levels from the vagina were evaluated.  As 
expected, local amphotericin B treatment reduced vaginal fungal burden by 
approximately 2 logs (Figure 24).  Surprisingly, treatment with NDGA was more 
effective than amphotericin B at reducing C. albicans growth, with approximately 
3 logs reduction.   However, treatment with indomethacin had no significant effect 
on fungal burden.  
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Figure 24.  Effect of eicosanoid inhibitors or antifungal drugs on C. 
albicans burden in experimental vaginitis.  On day 0, estrogenized mice were 
inoculated vaginally  with 5X106 candida per 10µl PBS.  On day 2, eicosanoid 
inhibitors (NDGA, Indomethacin) or antifungal drugs (amphotericin B) were 
administered vaginally at the concentration of 25 mg/kg/mice.  After 6 days of 
drug administration, the mice were euthanised on day 7 and the CFU were 
recovered after lavaging vaginal tissues twice with sterile PBS (each wash 50µl) 
followed by serial dilution and plating on SDA plates. Results are representative 
of three independent repeats. * P < 0.05 treated vs. untreated group.  
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 To examine effects of drug treatment on vaginal immune mediator 
production, PGE2 levels were analyzed in vaginal lavage samples. Compared 
with uninfected mice, vaginal tissues from mice infected with C. albicans showed 
induction of significant levels of PGE2 (Figure 25). Treatment with amphotericin B 
resulted in a reduction in PGE2 levels, which could be attributable to reduced 
fungal burden.  Treatment with NDGA had the most significant effect on reducing 
PGE2 levels, lowering to approximately 100 pg/ml.  Interestingly, indomethacin 
treated mice showed the induction of highest concentration of PGE2 induction, 
indicating this drug had no effect on inhibiting eicosanoid production.  
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Figure 25.  Effect of eicosanoid inhibitors or antifungal drugs on vaginal 
PGE2 levels during experimental vaginitis. On day 0, estrogenized mice were 
inoculated vaginally  with 5X106 candida per 10µl PBS.  On day 2, eicosanoid 
inhibitors (NDGA, Indomethacin) or antifungal drugs (amphotericin B) diluted in 
10µl of DMSO were administered vaginally at the concentration of 25 
mg/kg/mice. After 6 days of drug administration, the mice were euthanised on 
day 8 and the vaginal tissues were lavaged twice with sterile PBS (each wash 
50ul).  This homogenized tissue was centrifuged and the supernatant was used 
to measure PGE2 levels by ELISA. Results are representative of three 
independent repeats. * P < 0.05 infected vs. uninfected group. ** P < 0.05 treated 
vs. untreated group. 
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 We next analyzed local cytokines responses in vaginal homogenates. We 
observed a reduction in pro-inflammatory cytokine IFN-γ in infection mice 
compared with uninfected mice; however, overall levels of this cytokine are 
relatively low (Figure 26).  Treatment with NDGA partially restored IFN- 
production.  Infected mice also showed reduced IL-10, which can promote 
tolerogenic responses at mucosal surfaces. Treatment with NDGA partially 
restored IL-10 levels.  No significant levels of IL-4 or TGF- were detected in 
vaginal homogenates.  
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Figure 26.  Effect of eicosanoid inhibitors or antifungal drugs on vaginal 
cytokine levels during experimental vaginitis. On day 0, estrogenized mice 
were inoculated vaginally  with 5X106 candida per 10µl PBS.  On day 2, 
eicosanoid inhibitors (NDGA, Indomethacin) or antifungal drugs (amphotericin B) 
diluted in 10µl of DMSO were administered vaginally at the concentration of 25 
mg/kg/mice. After 6 days of drug administration, the mice were euthanised on 
day 8 and the vagina was excised and homogenized in 1ml sterile buffer 
containing PBS, 0.05% Triton X-100, and protease inhibitor.  This homogenized 
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tissue was centrifuged and the supernatant was used to measure cytokine levels 
by ELISA. Results are representative of three independent repeats. * P < 0.05 
treated vs. untreated group. ** P < 0.05 treated vs. untreated group. 
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To evaluate effects of eicosanoid inhibitors during systemic infection, mice 
were infected intravenously and treated with inhibitors by IP injection.  After 6 
days of daily administration of drugs, the mice were sacrificed on day 7 and 
kidneys analyzed for fungal burden.   After treatment with amphotericin B, lowest 
fungal burden was observed.  Compared with control mice, treatment with 
amphotericin B significantly reduced fungal burden in the kidney by 
approximately 4 logs (Figure 27). Treatment with NDGA also reduced fungal 
burden by approximately 2 logs.  However, we observed no effect with 
indomethacin treatment.   
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Figure 27. Effect of eicosanoid inhibitors or antifungal drugs on C. albicans 
kidney burden during systemic infection. On day 0, the mice were challenged 
by intravenous tail injection with C. albicans at the concentration of 2.5 x 105 
CFU/mouse in 250 µl of sterile endotoxin-free PBS.  From day 1 to day 6, mice 
were daily administered drugs via intraperitoneal route at a concentration of 5 
mg/kg for NDGA, indomethacin, and aspirin and  0.1 mg/kg for amphotericin B. 
After 7 days post-inoculation, the mice were sacrificed, the kidneys excised,  
homogenized and analyzed for fungal burden by serial dilution and plating onto 
SD plates. Results are representative of three independent repeats. * P < 0.05 
treated vs. untreated group. 
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Analysis of PGE2 levels in serum samples revealed increased levels in 
mice infected with C. albicans, compared with uninfected mice (Figure 28). 
Treatment with NDGA and amphotericin B resulted in a reduction in PGE2 levels, 
while indomethacin had little effect.  To determine the effect of eicosanoid 
inhibitors on immune responses during systemic infection, the spleens were 
harvested on day 7 following the daily drug treatment and cytokines were 
analyzed in restimulated splenocyte cultures. Compared with uninfected animals, 
there was a reduction in IFN-γ levels in infected mice (Figure 29).  Treatment 
with amphotericin B or NDGA restored IFN-γ production in splenocytes.  A similar 
trend was observed with pro-inflammatory cytokine TNF-.  Infected mice 
showed induction of this cyotkine, which was further increased with amphotericin 
B treatment.  Induction of the Th1 cytokine IL-12 was only observed in 
amphotericin B treated animals, which correlates with reduced fungal burden.  
Levels of IL-4 were extremely low, although levels correlated with fungal burden, 
with lowest levels observed with ampB treatment.  Overall this indicates that 
infection is associated with reduced Th1 promoting cytokines (IFNγand IL-12) 
and a reduction in fungal burden results in increased pro-inflammatory cytokines 
(IFN-γ and TNF-).   
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Figure 28.   Effect of eicosanoid inhibitors or antifungal drugs on serum 
PGE2 levels in mice systemically infected with C. albicans. On day 0, the 
mice were challenged by intravenous tail injection with C. albicans at the 
concentration of 2.5 x 105 CFU/mouse in 250 µl of sterile endotoxin-free PBS.  
From day 1 to day 6, they were daily administered drugs via intraperitoneal route 
at a concentration of 5 mg/kg for NDGA and indomethacin.  For amphotericin B, 
0.1 mg/kg/mice dose was used. On day 7, mice were sacrificed, their blood 
collected in BD yellow vacutainer and spun at 1000xg.  The serum was collected 
to perform ELISA using monoclonal PGE2 kit.  Results are representative of three 
independent repeats.  * P < 0.05 treated vs. untreated group. ** P < 0.05 treated 
vs. untreated group. 
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Figure 29. Effect of eicosanoid inhibitors or antifungal drugs on splenic 
cytokine levels in mice systemically infected with C. albicans.  On day 0, 
mice were challenged on day 1 via intravenous tail vein injection with C. albicans 
at the concentration of 2.5 x 105 CFU/mouse in 250 µl of sterile endotoxin-free 
PBS.  From day 2 to day 6, they were daily administered drugs via intraperitoneal 
route at a concentration of 5 mg/kg for NDGA and indomethacin.  For 
amphotericin B, 0.1 mg/kg/mice dose was used. On day 7, mice were sacrificed 
and their spleens were excised and the splenocytes were isolated. C. albicans 
were used at MOI 1:2 to stimulate the splenocytes.  After 2 h of incubation, 2.5 
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µg/ml of amphotericin B was added to prevent Candida overgrowth followed by 
further incubation of 16 h at 37°C, 5% CO2 incubator.  The supernatants were 
collected and the levels of cytokines were measured by ELISA. Results are 
representative of three independent repeats. * P < 0.05 treated vs. untreated 
group.   
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DISCUSSION 
 
PGE2 is a pleiotropic molecule that exerts various effects on immune 
responses depending on the microenvironment, tissue, and cells involved [134, 
230].   In addition, PGE2 and fungal PGEx promote germination and biofilm 
formation by C. albicans [231, 232].  The ability to form hyphae is required for 
virulence during systemic infection [13].  In addition, hyphal forms and ability to 
germinate are associated with symptomatic vaginal infections [233, 234]. 
However, the role of PGE2 and other eicosanoids towards immunomodulation in 
mucosal and systemic candidiasis is still largely unknown.  In vitro, exposure to 
eicosanoid inhibitors reduces fungal prostaglandin production, germination, and 
biofilm formation [154, 157, 226, 231].  At higher doses, these drugs can exert 
antifungal activity [152, 232, 235].  Therefore, we tested the ability of these drugs 
to inhibit fungal growth during mucosal and systemic infections and investigate 
effects on immune responses. 
Vulvovaginal candidiasis (VVC) is a very common infection among 
women.  C. albicans  is  the responsible causal organism in up to 80% of 
vaginitis cases [236].   Studies have shown that unlike systemic infection caused 
by C. albicans, vaginal infection is more associated with local immunity [74, 149, 
237].  Recent studies have reported an increased levels of PGE2 from recurrent 
VVC patients [150]. C. albicans has been shown to directly stimulate PGE2 
production from vaginal epithelial cells [152].  In addition, exogenous PGE2 
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administration increases C. albicans vaginal infection levels during experimental 
vaginitis [232].  However, the immunomodulatory effects of prostaglandins during 
this local immune response are poorly understood [238].   
Treatment with the non-specific LO/COX inhibitor NDGA locally during 
experimental vaginitis dramatically reduced fungal burden. At similar doses, 
NDGA was more effective than amphotericin B.  However, a non-selective COX 
inhibitor, indomethacin, had no effect, indicating that daily administration of drugs 
is not having a non-specific effect on fungal colonization levels.  At this point it is 
unclear if the differences in the fungal burden is a consequence of hyphae versus 
yeast  numbers that could result in differences in cfu burden.  Previous work by 
Noverr et al demonstrated the effect of COX-inhibitors towards the inhibition of 
Candida germination.   In both amphotericin B and NDGA treated mice, PGE2 
levels were reduced compared with untreated mice.  In the case of NDGA, this is 
likely due to inhibition of host cell and/or fungal PGE2 production as previously 
observed in vitro [154, 239, 240].  Interestingly, PGE2 production was elevated in 
the indomethacin treated mice.  This was unexpected; however, biphasic effects 
of indomethacin on prostaglandin production have been reported, with low doses 
promoting PGE2 production [241].  It is unknown what the local levels of 
indomethacin are during vaginal treatment, but this may be one explanation for 
these observations. Overall, fungal burden correlated with PGE2 levels.  This 
might be indicative of the fact that high concentrations of PGE2 are associated 
with susceptibility towards developing vaginitis.   
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Analysis of the associated local cytokines from the vaginal tissues showed 
that infection resulted in reduced pro-inflammatory IFN-γ production.  This has 
also been observed clinically, with decreased IFN-γ associated with recurrent 
vaginitis [242].  Treatment with either amphotericin B or NDGA resulted in 
increased IFN- γ, which may be due to reduced fungal burden, or due to reduced 
PGE2 levels, which can inhibit IFN- γ [243].  There was also reduced IL-10 
production in infected mice, which has been reported previously in experimental 
vaginitis [244]. IL-10 is an anti-inflammatory cytokine, which can inhibit activation 
of innate effector cells, which mediate the symptoms of vaginitis. IL-10 levels 
tend to correlate with fungal burden, as infection induces pro-inflammatory 
responses [245]. Accordingly, Amphotericin B and NDGA treatment partially 
rescued IL-10 production. While PGE2 is a known inducer of IL-10, we 
hypothesize that the lack of fungal burden and antigenic stimulation is 
responsible for reduced IL-10 production [246].  Overall, these results 
emphasized the fact that increased levels of PGE2 are associated with increased 
fungal burden and cytokines associated with local immune responses during 
infection. 
 Systemic candidiasis is a clinically important infection and is associated 
with high mortality rates [2, 3].  Both innate and adaptive immunity is required to 
mount a protective response to infection. Treatment of mice with amphotericin B 
reduced kidney fungal burden.  In addition, treatment with NDGA also reduced C. 
albicans levels. This was associated with a reduction in serum PGE2 levels.  
Similar to the vaginal infection, overall C. albicans levels correlated with PGE2 
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levels. Studies have shown the role of prostaglandins in generating non-
protective responses by dampening anti-fungal defenses [189]. We also 
observed that treatment with amphotericin B and NDGA was associated with 
elevated splenic IFN-γ and IL-12, which are required for generation of protective 
Th1 responses during systemic infection [247].  High fungal burden in untreated 
mice was associated with slightly increased IL-4 and low IL-12, indicative of a 
non-protective Th2 response.  This association of fungal burden with Th1 vs. Th2 
responses has been demonstrated in previous work with mice having 
disseminated candidiasis [74, 248]. Unlike like NDGA and amphotericin B, 
indomethacin was not able to reduce the levels of PGE2 and the balance tilted 
more towards non-protective response.  This may be due to alternative effects of 
indomethacin on the host immune response.  For example, β-glucan, a fungal 
cell wall component, combined with indomethacin can result in 
immunocompromise leading to sepsis from the GI tract and mortality in mice 
[249].  The lethality is strongly related to disruption of the cytokine network.  
Similar results were observed with killed whole cells of C. albicans [250].  
Therefore, different eicosanoid inhibitors may have unforeseen effects on global 
inflammatory responses and must be tested in vivo to determine efficacy against 
fungal infection. 
Although our study points to the fact that PGE2 is one of the key 
molecules involved in the process of exacerbating a progressive form of 
disseminated candidiasis and aids in elevating Th2 responses, the underlying 
mechanism for this process is not yet clear.   From the previous studies showing 
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the negative role played by the Th2 cytokines during disseminated candidiasis, 
inhibition of PGE2 might prove beneficial for the host to clear-up the infection 
[205, 251]. It is unclear whether NDGA works to inhibit C. albicans growth by 
inhibiting PGE2 production, or whether direct effects of NDGA on fungal killing 
resulting in reduced fungal burden causes a reduction in PGE2.  Regardless, the 
effect of this drug is beneficial and may exert synergistic effects on reducing 
fungal levels in vivo in combination with a traditional antifungal.  Synergism 
between amphotericin B and NDGA has already been observed in vitro [232].  
This is extremely important as resistance to both polyene drugs (amphotericin B 
drug class) and azoles are on the rise. New therapeutic strategies targeting both 
PGE2 and fungal viability may be beneficial for treating fungal infections under 
these kinds of circumstances. 
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GENERAL CONCLUSION 
 
Prostaglandins are pleiotropic compounds playing an array of 
immunomodulatory roles in the mammals.  Depending on the type of interaction 
and the receptors involved, they can have multiple effects on different cells types 
at a very low (nanomolar) concentrations [134, 230].  Their roles have been 
widely associated with the effector functions of many immune cells including 
those of the innate immune system (macrophages, neutrophils), cells that bridge 
innate and adaptive responses (dendritic cells, epithelial cells), and adaptive 
immunity (T cells, B cells) [252].  They regulate both acute inflammatory 
responses as well as chronic inflammation and memory immunity. PGE2 
specifically influences phagocytosis and intracellular killing of microbial 
pathogens as well as cytokine release from macrophages.  PGE2 also regulates 
release of effector molecules, migration, maturation and secretion of 
immunomodulatory compounds from dendritic cells and lymphocytes [165, 167, 
253-255].   
The fact that C. albicans produces both endogenous PGE2-like 
compounds as well as authentic PGE2 from host arachidonic acid suggests that 
this fungal pathogen may directly influence host responses during colonization 
and/or infection.   Production of eicosanoids by host cells can also be induced 
upon interaction by fungal pathogens.  C. albicans has been shown to be able to 
induce the activation and transcription of host PGE2 production from various 
immune cells such as macrophages, endothelial cells, and splenocytes [161, 
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188, 189].  Therefore both fungal derived and host derived eicosanoids can 
participate in driving immune responses during fungal infection.  Our hypothesis 
is that Production of oxylipins by both fungi and host modulate the host-pathogen 
interaction in favor of non-resolving infection or persistence.   The goal of this 
thesis was to determine the immunomodulatory roles of host and fungal 
eicosanoids during interactions of C. albicans with the host.     For this purpose 
we studied the role of prostaglandins in vitro (with dendritic cells and 
macrophages) as well as in vivo using mucosal and systemic models.     
From our studies with the effects of exogenous PGE2 on dendritic cell-
Candida interactions, the early cytokine analysis with both JAWSII cells and 
primary pDCs and mDCs revealed upregulation of Th2 cytokines (IL-4) and 
down-regulation of Th1 cytokines (IL-12) in the presence of hyphae.  This is in 
agreement with the previous data reporting a bias towards non-protective Th2 
cytokine responses in macrophages and monocytes in the presence of hyphae, 
but not yeast [80, 219, 220, 253-257].  However, the presence of PGE2 was 
required for robust Th2 cytokine production from DCs in the presence of hyphae, 
which is an activity previously reported for PGE2 [183].  Later cytokine analysis 
also showed a shift towards a DC2 phenotype in primary DCs stimulated with 
prostaglandins.  The only significant difference in immune mediator production 
that varied between yeast and hyphae pulsed cells was in host PGE2 production.  
Hyphae stimulated significant production at 18 h, the time point used to harvest 
DCs for adoptive transfer.  This indicates that hyphae can prime DCs for PGE2 
release, which could influence nearby immune cells. 
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This difference in the pattern of PGE2 induction could be due to differential 
PRR signaling.  DCs recognize yeast and hyphal form of C. albicans via TL4 and 
TLR2 receptors [80, 115, 116].  Also, studies have indicated that C. albicans 
signaling via TLR2 pathway leads to the production of PGE2 from the host and 
causes persistent type of infection [189].  Future studies in this area would 
involve examining DC PGE2 production in the presence of yeast and hyphae in 
PRR knockout mice. Overall, these data demonstrate that depending on the 
morphotypes (yeast or hyphal form), the DCs have the ability to modulate the 
immune responses in presence of exogenously added prostaglandins. 
We observed evidence from early cytokine analysis that effects of 
prostaglandin exposure are not limited to simply effects on Th1 and Th2 
mediators.  In addition, we demonstrated that pro-inflammatory cytokines IL-6 
and IL-15 were upregulated in the hyphae/PGE2 group.  Early expression of 
SOCS-3, a suppressor of cytokine, involved in promoting a DC2 phenotype was 
also upregulated during this time point. [184].  This suggests that PGE2 exposure 
can also stimulate pro-inflammatory mediators and that host cells counter-
regulate this with SOCS synthesis. In addition, the CD86 expression was greatly 
increased in primary DCs pulsed with hyphae in the presence of PGE2, which 
indicative of maturation and a heightened activation state.  Therefore, it was 
unclear as to how these pulsed DCs would regulate subsequent adaptive 
responses upon vaccination.   
 For DC vaccination, two rounds of priming were necessary to 
induce robust responses. We showed that yeast pulsed pDCs imparts protection 
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whereas mDCs are less protective in mice with systemic infection.  This non-
protection was associated with splenic and kidney Th2 responses and at later 
stages, exacerbated local Th17 responses accompanied by uncontrolled fungal 
growth at the site of infection.  Another major difference between the responses 
to mDCs and pDCs was evident in the kidney Th17 cytokines. Although we 
observed slight protection with double adoptive transfer with mDCs pulsed with 
yeast, there was dramatic IL-17 and IL-23 cytokine staining in the kidneys. The 
ability of mDCs to promote Th17 responses compared with pDCs has been 
reported previously [79].  Therefore, mDCs may not be appropriate for fungal 
vaccination strategies and these results underscore the importance and 
variability of DC subsets. 
 Our results are in alignment with other studies indicating that both IL-23 
and IL-17 can inhibit neutrophil antifungal activity resulting in pathological form of 
inflammation associated with impaired antifungal resistance [79]. Therefore, 
although neutrophils were recruited to the kidneys, the antifungal activity is likely 
diminished, as indicated by the high fungal burden. To investigate this concept 
further, it would be necessary to isolate kidney or bloodstream PMNs and 
examine antifungal activity in vitro. While the Th17 response is required to 
defend against mucosal and acute systemic infections, ours is the first study to 
report presence of Th17 cytokines in the mice kidneys of vaccinated mice during 
systemic candidiasis and its associated lack of protection.  This indicates that IL-
17 helps initiate protective innate responses during C. albicans infections, but if 
left unchecked, may exacerbate immunopathological inflammation.  Future 
 
 150
studies examining the role of Th17 responses during afferent vs. efferent 
responses are necessary to investigate this possibility.  
We examined the effect of PGE2 and PGEx during the interaction of C. 
albicans with the macrophage cell line, RAW264.7.  In this case, we used PGEx 
derived from arachidonic acid, which is 99.9% PGE2.   Both the fungal derived 
and commercially available prostaglandins inhibited phagocytosis of C. albicans, 
while increasing intracellular survival in activated macrophages. Interestingly, 
these effects were more dramatic with PGEx, compared with PGE2.  These 
experiments confirmed that host PGE2 and fungal PGEx aid in overcoming 
antifungal defenses of macrophages.  The fact that PGEx produced a more 
potent response may be due to effects of the endogenous PGE2 cross-reactive 
compound that is co-isolated with fungal PGE2.  However, we did not observe 
such dramatic differences in responses to PGEx vs. PGE2 with dendritic cells in 
terms of promoting non-protective responses.  To investigate the variable effects 
of specifically endogenous PGEx on host cells, it would be necessary to isolate 
the compound in enough quantity to perform experiments.  Without addition of 
exogenous arachidonic acid, very small quantities of PGEx are produced.  
Therefore, these experiments would be difficult to perform.   
We have made some advancement in our understanding on how C. 
albicans interacts with RAW264.7 cells in presence of prostaglandins, but large 
gaps in our knowledge still remains to verify the underlying mechanism. Both 
reactive oxygen and nitrogen species (ROI/RNI) production contribute to the 
candidicidal activity of macrophages, with nitric oxide and peroxynitrite exhibiting 
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the strongest antifungal activity. Our data indicate that a nitric oxide synthase 
inhibitor slightly reduced NO production from macrophages, which resulted in 
increased fungal burden in control and PGE2 treated groups.  However, with 
PGEx treated groups, we observed no increase in fungal burden in the presence 
of the inhibitor.  This may be due to the fact that fungal burden was already 
maximal with PGE2 treatment.  However, neither PGE2 nor PGEx alone inhibited 
nitric oxide or peroxynitrite production; therefore, this is not the mechanism of 
action of these compounds.   
Future studies should be directed at examining non-oxidative mechanisms 
that mediate intracellular killing of C. albicans.  While investigators have 
demonstrated that C. albicans traffics to the phagolysosome, there may be some 
variation in microenvironment within this compartment that impacts killing [216].   
For example, it was recently shown that there is inhibition of the C. albicans 
phagosome fusing with compartments enriched in the lysobisphosphatidic acid  
[258].  In comparing a wildtype and hyphal deficient mutant, the wildtype strain 
displayed additional specific survival strategies to prevent its targeting to 
compartments displaying late endosomal/lysosomal features, such as induction 
of active recycling out of phagosomes of the lysosomal membrane protein LAMP-
1, the lysosomal protease cathepsin D at later time points.  Detailed microscopic 
and cell trafficking experiments are needed to further examine the effects of 
prostaglandins in the intracellular fate of C. albicans.   
 For synthesis of prostaglandins from arachidonic acid precursors, two 
cyclooxygenase (COX) enzymes, COX-1 and COX-2, are involved.  COX-1 is 
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expressed constitutively and is responsible for steady-state eicosanoid 
production whereas COX-2 is the inducible form and responsible for 
inflammatory eicosanoid production [230].   Previous studies have demonstrated 
that C. albicans induces PGE2 production via COX-2 in vitro [161].  This enzyme 
can be inhibited by treatment with various nonsteroidal anti-inflammatory drugs 
(NSAIDS) including aspirin, indomethacin, naproxen, etc. In addition, certain 
plant polyphenols inhibit COX activity, including resveratrol and NDGA, which 
also inhibits lipoxygenase.  We evaluated the effects of eicosanoid inhibitors 
(both an NSAID and plant polyphenol) to determine the effects of host 
eicosanoids in vivo in mucosal and systemic infection models.  It was important 
to test several infection models as immune responses to C. albicans infections 
are distinct depending on the tissue.   
C. albicans vaginitis is a superficial mucosal infection that does not follow 
the normal paradigm of protective immunity [259]. While cell-mediated immunity 
is considered the predominant host defense mechanism against other mucosal 
candidal infections, studies have revealed a lack of a protective role for adaptive 
immunity. Instead aberrant innate responses to C. albicans colonization are 
responsible, mediated by epithelial cells and neutrophils [260].  In terms of 
control of the aberrant response, it is believed that immunoregulatory activities of 
local dendritic cells participate in promoting tolerance to the colonization state.  In 
the experimental vaginitis model, upon treatment with NDGA and indomethacin, 
our studies demonstrated decreased fungal burden and PGE2 levels. Treatment 
with either NDGA resulted in increased IFN-γ, which may be due to reduced 
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fungal burden, or due to reduced PGE2 levels, which can inhibit IFN- [243].  
NDGA treatment also partially restored IL-10 production.  IL-10 is an anti-
inflammatory cytokine, which can inhibit activation of innate effector cells, which 
mediate the symptoms of vaginitis. IL-10 levels tend to correlate with reduced 
fungal burden, as infection induces pro-inflammatory responses [244]. While 
PGE2 is a known inducer of IL-10, we hypothesize that the lack of fungal burden 
and antigenic stimulation is responsible for reduced IL-10 production [246]. 
Overall, these results emphasized the fact that increased levels of PGE2 are 
associated with increased fungal burden and cytokines associated with local 
immune responses during infection. 
Future studies focused on the role of PGE2 in vaginitis could also be 
examine the growth state of C. albicans in the vaginal tract as PGE2 also 
enhances morphogenesis and biofilm formation.  Recently, it was reported that 
C. albicans forms biofilms on the vaginal mucosa.  However, the role of biofilms 
in pathogenesis during vaginitis is unknown [261, 262].  In line with this, the role 
of estrogen in this model should be investigated, which is required for a robust 
vaginal infection.  Estrogen has direct effects on inducing C. albicans 
morphogenesis [263].  PGE2 stimulates expression and activity of aromatase, the 
enzyme that is responsible for a key step in the biosynthesis of estrogens [264].  
This results in local production of estrogen, which induces PGE2 formation and 
establishes a positive feedback cycle.  Therefore, effects on both the fungus and 
host may work together to promote vaginal fungal growth and infection. 
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 We also investigated effects of eicosanoid inhibitors during systemic 
candidiasis. The ability to clear or control a systemic infection with Candida is 
dependent on the elaboration of a protective adaptive immune response, 
characterized by induction of Th1 cells and production of pro-inflammatory 
cytokines.  A non-protective response is characterized by expansion of Th2 cells 
and production of Th2 cytokines [222]. Treatment of mice with NDGA reduced C. 
albicans level in the kidney, which was associated with a reduction in serum 
PGE2 levels.  We also observed that treatment with NDGA was associated with 
elevated splenic IFN-γ and IL-12, which are required for generation of protective 
Th1 responses during systemic infection [247]. Unlike like NDGA, indomethacin 
was not able to reduce the levels of PGE2 and the balance tilted more towards 
non-protective response. While this may be due to alternative effects of 
indomethacin in protective inflammatory responses, this may also be due to 
ineffectiveness at directly killing C. albicans or inhibiting fungal prostaglandin 
production during infection.  Pharmacologically, this drug may not access C. 
albicans at the site of infection or may lose efficacy in vivo.  There is the 
possibility that using nanotechnology or lipid-based delivery systems may be 
more effective. Overall, these studies suggested that manipulation of eicosanoid 
production are effective at reducing fungal burden without suppressing 
inflammatory response and inhibit fungal growth at same time. 
 Although the work presented in this dissertation has provided an 
insight on the immunomodulatory role of prostaglandins during Candida-host 
interactions, many questions still require further investigation.   It would be 
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important to test responses to C. albicans mutants lacking the ability to produce 
eicosanoids would be affected.  For this purpose, all the genes responsible for 
production of eicosanoids in C. albicans need to be identified and mutants have 
to be made to study the downstream response when interacting with the host 
cells.  However, the enzymes and metabolic pathways of fungal eicosanoid 
production are mostly unknown.  This is due largely to differences between 
fungal and mammalian enzymes at both the nucleic and amino acid sequence 
level.  So far, OLE2  (fatty acid desaturase) and FET3 (multicopper oxidase) has 
been associated with decreased PGE2 production but they did not completely 
abrogate it [154]. In addition, a bifunctional LTA4 hydrolase was cloned and 
characterized from S. cerevisiae [265].  This enzyme possessed 42% identity 
with mammalian leukotriene A4 (LTA4) hydrolase and produced LTB4 from LTA4 
in vitro [266]. There exists a homolog of LTA4 hydrolase in C. albicans, which 
can produce LTB4 in vitro.  Therefore, future studies could focus on effects of 
fungal leukotrienes during infection, which may exert completely different effects 
on the host response compared with prostaglandins.   
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Abstract 
 
IMMUNOMODULATORY EFFECT OF HOST AND FUNGAL EICOSANOIDS 
DURING HOST-PATHOGEN INTERACTIONS WITH CANDIDA ALBICANS 
 
by 
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August 2010 
Advisor:   Dr. Mairi C. Noverr 
Major:      Immunology and Microbiology 
Degree:   Doctor of Philosophy 
 Candida albicans, an opportunistic fungal pathogen, poses a significant 
clinical threat to immunocompromised patients. Diseases associated with this 
fungus ranges from superficial mucosal infection to life-threatening systemic 
candidiasis.  The mechanisms by which Candida persists at mucosal surfaces in 
the face of an adaptive response are unclear. Candida produces 
immunomodulatory oxylipins that cross-react functionally with host eicosanoids, 
which are considered to play important role in regulating innate and adaptive 
immune responses.  Our objective was to characterize the role of prostaglandins 
produced by the host and this fungus during host pathogen interactions, both in 
vitro with dendritic cells (DCs) and macrophages, and in vivo during 
pathogenesis. At early time point, there was upregulation of Th2 cytokines IL-4, 
IL-10, and IL-13 by both plasmacytoid and myeloid DCs in the presence of 
hyphae and PGE2.  At later time points, fungal or host PGE2 treatment resulted in 
decreased Th1 cytokine production (IL-12 and IL-6) and slightly increased Th2 
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cytokine production (IL-4). DC vaccination experiments demonstrated that yeast 
pulsed DCs imparted protection, which was abrogated with exposure to host or 
fungal PGE2.  Non-protective responses were associated with Th2 cytokine 
production, and at later stages, exacerbated Th17 responses accompanied by 
uncontrolled fungal growth. Ours is the first study to report presence of Th17 
cytokines in the mice kidneys during systemic candidiasis and its associated lack 
of protection. We also demonstrated that during the interaction of C. albicans 
with the macrophages, PGE2 and PGEx decreased phagocytosis and increased 
intracellular survival. We also investigated the effects of eicosanoid inhibitors 
during mucosal and systemic infection models.  During experimental C. albicans 
vaginitis, treatment with inhibitors locally resulted in decreased fungal burden and 
PGE2 levels.  Similar results were observed during systemic infection, which 
correlated with restoration of Th1 cytokines.  These studies suggested that 
balanced manipulation with eicosanoid production can work without suppressing 
inflammatory response and inhibit fungal growth at same time. This could provide 
newer avenues for developing novel pharmacological intervention strategies to 
treat C. albicans infections. 
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